

# CURRICULUM VITAE

(以下資料中英文擇一回覆即可)

## PERSONAL

NAME(姓名，含英譯)

余明隆

Ming-Lung Yu, M.D., PH.D.



## PROFESSIONAL APPOINTMENT (現職，含英譯)

1994-present	Visiting Staff 主治醫師	Hepatobiliary Division, Department of Medicine, Kaohsiung Medical University Hospital 高雄醫學大學附設中和紀念醫院 肝膽胰內科
2020-present	Chair Professor 講座教授	Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan 高雄醫學大學 醫學院
2019-present	Chief 主任	Hepatitis Research Center, Kaohsiung Medical University, Kaohsiung, Taiwan 高雄醫學大學 肝炎研究中心
2020-present	Honorary Chair Professor 榮譽講座教授	National Sun Yat-Sen University, Kaohsiung, Taiwan 國立中山大學
2015-present	Professor 合聘教授	Institute of Biopharmaceutical Sciences, National Sun Yat-Sen University, Kaohsiung, Taiwan 國立中山大學 生物醫學研究所
2018-present	Expert 專家	Medical Dispute Evaluation Team, Medical Review Committee of Medical Affairs Division, Ministry of Health and Welfare 衛生福利部 醫事審議委員會醫事鑑定小組
2019-present	Reserved Accreditation Surveyor 儲備評鑑委員	Hospital Accreditation and Teaching Hospital Accreditation of Ministry of Health and Welfare 衛生福利部 醫院評鑑及教學醫院評鑑
2022-present	Committee 委員	Liver Cancer and Hepatitis Prevention Committee Ministry of Health and Welfare

**EDUCATION(學歷)**

學校名稱	國別	主修學門系所	學位	起訖年月(西元年/月)
高雄醫學院	中華民國	醫學系	醫學士	1982 / 09 至 1989 / 07
高雄醫學院	中華民國	醫學研究所	博士	1992 / 08 至 2000 / 07

**WORKING EXPERIENCE (經歷)**

服務機構	服務部門／系所	職稱	起訖年月(西元年/月)
高雄醫學大學附設醫院	內科	住院醫師、 總住院醫師	1989 / 08 至 1994 / 07
高雄市長小港醫院	職業病科	主任	1998 / 08 至 2002 / 07
高雄醫學大學	醫學系內科學	助理教授	2000 / 08 至 2003 / 07
高雄醫學大學	醫學系	副教授	2003 / 08 至 2006 / 07
高雄醫學大學附設醫院	保健科	主任	2003 / 08 至 2009 / 07
高雄市長大同醫院	籌備處	主任委員	2009 / 08 至 2009 / 12
高雄市長大同醫院	肝膽胰內科	院長	2010 / 01 至 2012 / 07
高雄醫學大學附設醫院	行政	副院長	2012 / 08 至 2015 / 07
高雄醫學大學附設醫院	肝膽胰內科	主任	2015 / 08 至 2016 / 07
美國哈佛大學	醫學院	客座教授	2016 / 08 至 2017 / 07
高雄醫學大學	行政	副校長	2018 / 07 至 2021 / 08
高雄醫學大學	醫學院	特聘教授	2013 / 08 至 2020 / 07
國立陽明交通大學	生物科技學系	合聘教授	2017 / 08 至 2021 / 07

**MAJOR RESEARCH AREA(研究領域)**

1. 內科學	2. 肝膽胰內科	3. 超音波診斷學	4. 消化器內視鏡
--------	----------	-----------	-----------

**PUBLICATION(In the nearest 5 years)(發表、出版物)****I. Refereed Paper****Published online First Author or Corresponding Author**

1. Yeh ML, Liang PC, Trinh S, Huang CI, Huang CF, Hsieh MY, Huang JF, Dai CY, Chuang WL, Nguyen MH\*, **Yu ML\***. 2021. Body weight changes in treated hepatitis B patients switching to tenofovir alafenamide\*. J Formos Med Assoc. 2021 Oct 5;S0929-6646(21)00431-9. Epub ahead of print. PMID: 34625346. (2020, IF: 3.282, Medicine, General & Internal: 53/167=31.74%)
2. Jang TY, Wang HH, Huang CF, Dai CY, Huang JF, Chuang WL, Kuo CY\*, **Yu ML\***. 2022. Clinical characteristics and treatment outcomes of SARS-CoV-2 delta variant outbreak, Pingtung, Taiwan, June 2021. J Formos Med Assoc. 2022 Jan 17;S0929-6646(22)00008-0. doi: 10.1016/j.jfma.2022.01.008. Epub ahead of print. PMID: 35067428; PMCID: PMC8761556. (2020, IF: 3.282, Medicine, General & Internal: 53/167=31.74%)
3. Lo CC, Huang CF, Cheng PN, Tseng KC, Chen CY, Kuo HT, Huang YH, Tai CM, Peng CY, Bair MJ, Chen CH, Yeh ML, Lin CL, Lin CY, Lee PL, Chong LW, Hung CH, Chang TS, Huang

- JF, Yang CC, Hu JT, Lin CW, Chen CT, Wang CC, Su WW, Hsieh TY, Lin CL, Tsai WL, Lee TH, Chen GY, Wang SJ, Chang CC, Mo LR, Yang SS, Wu WC, Huang CS, Hsiung CK, Kao CN, Tsai PC, Liu CH, Lee MH, Liu CJ, Dai CY, Chuang WL, Lin HC, Kao JH, **Yu ML\***; TACR investigators. **2022**. Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4-6 infection: Real-world evidence from a nationwide registry in Taiwan. *J Formos Med Assoc.* 2022 Feb 2;S0929-6646(22)00032-8. doi: 10.1016/j.jfma.2022.01.012. Epub ahead of print. PMID: 35123849. **(2020, IF: 3.282, Medicine, General & Internal: 53/167=31.74%)**
4. Tsai PC, Dai CY, Huang CI, Yeh ML, Huang CF, Hsieh MH, Yang JF, Hsu PY, Liang PC, Lin YH, Jang TY, Hsieh MY, Lin ZY, Chen SC, Huang JF, **Yu ML\***, Chuang WL\*, Chang WY. **2022**. Low disease awareness as a contributing factor to the high prevalence of hepatitis C infection in Tzukuán, a hyperendemic area of southern Taiwan. *Kaohsiung J Med Sci.* 2022 Apr 29. doi: 10.1002/kjm2.12552. Epub ahead of print. PMID: 35485737. **(2020, IF: 2.744, Medicine, Research & Experimental: 93/140=66.43%)**
5. Sun HY, Chiang C, Huang SH, Guo WJ, Chuang YC, Huang YC, Yang CJ, Su LH, Chen YT, Chen YW, Hsu FC, Ho SY, Liu WC, Su YC, Chang SY, Hsiao CF, Hung CC\*, **Yu ML\***. **2022**. Three-Stage Pooled Plasma Hepatitis C Virus RNA Testing for the Identification of Acute HCV Infections in At-Risk Populations. *Microbiol Spectr.* 2022 May 2:e0243721. doi: 10.1128/spectrum.02437-21. Epub ahead of print. PMID: 35499354. **(2020, IF: 7.171, Microbiology: 18/136=13.24%)**
6. Sun HY, Liu WD, Wang CW, Wei YJ, Lin KY, Huang YS, Su LH, Chen YT, Liu WC, Su YC, Chen YW, Chuang YC, Lu PL, Hung CC, **Yu ML\***. Performance of Hepatitis C Virus (HCV) Core Antigen Assay in the Diagnosis of Recently Acquired HCV Infection among High-Risk Populations. *Microbiol Spectr.* 2022 May 17:e0034522. doi: 10.1128/spectrum.00345-22. Epub ahead of print. PMID: 35579445. **(2020, IF: 7.171, Microbiology: 18/136=13.24%)**

#### Published online Co-author

7. Younossi ZM\*, Yilmaz Y, **Yu ML**, Wai-Sun Wong V, Fernandez MC, Isakov VA, Duseja AK, Mendez-Sanchez N, Eguchi Y, Bugianesi E, Burra P, George J, Fan JG, Papatheodoridis GV, Chan WK, Alswat K, Saeed HS, Singal AK, Romero-Gomez M, Gordon SC, Roberts SK, El Kassas M Sr, Kugelmas M, Ong JP, Alqahtani S, Ziavee M, Lam B, Younossi I, Racila A, Henry L, Stepanova M; Global NASH Council. **2021**. Clinical and Patient Reported Outcomes from Patients with Non-alcoholic Fatty Liver Disease Across the World: Data from the Global NASH/NAFLD Registry. *Clin Gastroenterol Hepatol.* 2021 Nov 9;S1542-3565(21)01183-6. doi: 10.1016/j.cgh.2021.11.004. Epub ahead of print. PMID: 34768009. **(2020, IF: 11.382, Gastroenterology & Hepatology: 8/92=8.70%)**
8. Huang YH, Chan C, Lee HW, Huang C, Chen YJ, Liu PC, Lu SN, Chuang WL, Huang JF, **Yu ML**, Koshiol J, Lee MH. **2022**. Influence of Nonalcoholic Fatty Liver Disease With Increased Liver Enzyme Levels on the Risk of Cirrhosis and Hepatocellular Carcinoma. *Clin Gastroenterol Hepatol.* 2022 Feb 3;S1542-3565(22)00105-7. doi: 10.1016/j.cgh.2022.01.046. Epub ahead of print. PMID: 35124270. **(2020, IF: 11.382, Gastroenterology & Hepatology: 8/92=8.70%)**
9. Liu TW, Huang CF, Tsai PC, Yeh ML, Jang TY, Huang JF, Dai CY, **Yu ML**, Chuang WL\*. **2022**. The compound annual growth rate of the fibrosis-4 index in chronic hepatitis B patients. *Kaohsiung J Med Sci.* 2022 Apr 11. doi: 10.1002/kjm2.12543. Epub ahead of print. PMID: 35403363. **(2020, IF: 2.744, Medicine, Research & Experimental: 93/140=66.43%)**

#### 2022 First Author or Corresponding Author

10. Dai CY, Yeh ML, **Yu ML\***. **2022**. An EASL position paper for systemic treatment of hepatocellular carcinoma: Go forward courageously. *J Hepatol.* 2022 Feb;76(2):478-480. Epub 2021 Sep 4. PMID: 34492252. **(2020, IF: 25.083, Gastroenterology & Hepatology: 2/92=2.17%)**
11. Dai CY, Chuang WL, **Yu ML\***. **2022**. Predicting portal thrombosis in cirrhosis: Some issues. *J Hepatol.* 2022 Jan;76(1):224-225. Epub 2021 Aug 27. PMID: 34461209. **(2020, IF: 25.083, Gastroenterology & Hepatology: 2/92=2.17%)**
12. Huang CF, Tseng KC, Cheng PN, Hung CH, Lo CC, Peng CY, Bair MJ, Yeh ML, Chen CH, Lee PL, Lin CY, Kuo HT, Chen CT, Yang CC, Huang JF, Tai CM, Hu JT, Lin CL, Su WW, Tsai WL, Huang YH, Cheng CY, Lin CL, Wang CC, Yang SS, Mo LR, Chen GY, Chang CC, Wang SJ, Huang CS, Hsieh TY, Lin CW, Lee TH, Chong LW, Huang CW, Chang SN, Tsai MC, Hsu SJ, Kao JH, Liu CJ, Liu CH, Lin HC, Lee MH, Tsai PC, Dai CY, Chuang WL, Chen CY, **Yu ML\***. **2022**. Impact of sofosbuvir-based direct-acting antivirals on renal function in chronic hepatitis C patients with impaired renal function: a large cohort study from the

- nationwide HCV Registry Program (TACR). *Clin Gastroenterol Hepatol*. 2022 May;20(5):1151-1162.e6. doi: 10.1016/j.cgh.2021.07.037. Epub 2021 Jul 30. PMID: 34333150. (2020, IF: 11.382, Gastroenterology & Hepatology: 8/92=8.70%)
13. Tsai YS, Huang CI, Tsai PC, Yeh ML, Huang CF, Hsieh MH, Liu TW, Lin YH, Liang PC, Lin ZY, Chen SC, Huang JF, Chuang WL, Dai CY, **Yu ML\***. 2022. Circulating Let-7 Family Members as Non-Invasive Biomarkers for Predicting Hepatocellular Carcinoma Risk after Antiviral Treatment among Chronic Hepatitis C Patients. *Cancers (Basel)*. 2022 Apr 16;14(8):2023. doi: 10.3390/cancers14082023. PMID: 35454929. (2020, IF: 6.639, Oncology: 51/242= 21.07%)
  14. Lau G\*, **Yu ML\***, Wong G, Thompson A, Ghazinian H, Hou JL, Piratvisuth T, Jia JD, Mizokami M, Cheng G, Chen GF, Liu ZW, Baatarkhuu O, Cheng AL, Ng WL, Lau P, Mok T, Chang JM, Hamid S, Dokmeci AK, Gani RA, Payawal DA, Chow P, Park JW, Strasser SI, Mohamed R, Win KM, Tanwandee T, Sarin SK, Omata M. 2022. Correction to: APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy. *Hepatol Int*. 2022 Jan 25. doi: 10.1007/s12072-022-10301-2. Epub ahead of print. Erratum for: *Hepatol Int*. 2021 Oct;15(5):1031-1048. PMID: 35076895. (2020, IF: 6.047, Gastroenterology & Hepatology: 24/92=26.09%)
  15. Huang JF, Hsieh MY, Wei YJ, Hung JY, Huang HT, Huang CI, Yeh ML, Huang CF, Jang TY, Hsu PY, Liang PC, Dai CY, Lin ZY, **Yu ML\***, Chuang WL\*. 2022. Towards a safe hospital: hepatitis C in-hospital micro-elimination program (HCV-HELP study). *Hepatol Int*. 2022 Feb;16(1):59-67. Epub 2021 Nov 30. PMID: 34850326; PMCID: PMC8631565. (2020, IF: 6.047, Gastroenterology & Hepatology: 24/92=26.09%)
  16. Huang CF, Tyng-Yuan J, Jun DW, Ahn SB, An J, Enomoto M, Takahashi H, Ogawa E, Yoon E, Jeong SW, Shim JJ, Jeong JY, Kim SE, Oh H, Kim HS, Cho YK, Kozuka R, Inoue K, Cheung KS, Mak LY, Huang JF, Dai CY, Yuen MF, Nguyen MH, **Yu ML\***. 2022. On-treatment gamma-glutamyl transferase predicts the development of hepatocellular carcinoma in chronic hepatitis B patients. *Liver Int*. 2022 Jan;42(1):59-68. Epub 2021 Nov 29. PMID: 34687130. (2020, IF: 5.828, Gastroenterology & Hepatology: 25/92=27.17)
  17. Chen CT, Lu MY, Hsieh MH, Tsai PC, Hsieh TY, Yeh ML, Huang CI, Tsai YS, Ko YM, Lin CC, Chen KY, Wei YJ, Hsu PY, Hsu CT, Jang TY, Liu TW, Liang PC, Hsieh MY, Lin ZY, Huang CF, Huang JF, Dai CY, Chuang WL, Shih YL, **Yu ML\***. 2022. Outreach onsite treatment with a simplified pangenotypic direct-acting anti-viral regimen for hepatitis C virus micro-elimination in a prison. *World J Gastroenterol*. 2022 Jan 14;28(2):263-274. PMID: 35110949; PMCID: PMC8776526. (2020, IF: 5.742, Gastroenterology & Hepatology: 28/92=30.43%)
  18. Lu MY, Yeh ML, Huang CI, Wang SC, Tsai YS, Tsai PC, Ko YM, Lin CC, Chen KY, Wei YJ, Hsu PY, Hsu CT, Jang TY, Liu TW, Liang PC, Hsieh MY, Lin ZY, Chen SC, Huang CF, Huang JF, Dai CY, Chuang WL, **Yu ML\***. 2022. Dynamics of cytokines predicts risk of hepatocellular carcinoma among chronic hepatitis C patients after viral eradication. *World J Gastroenterol* 2022 Jan 7;28(1):140-153. PMID: 35125824; PMCID: PMC8793012. (2020, IF: 5.742, Gastroenterology & Hepatology: 28/92=30.43%)
  19. Cheng PN, Mo LR, Chen CT, Chen CY, Huang CF, Kuo HT, Lo CC, Tseng KC, Huang YH, Tai CM, Peng CY, Bair MJ, Chen CH, Yeh ML, Lin CL, Lin CY, Lee PL, Chong LW, Hung CH, Chang TS, Huang JF, Yang CC, Hu JT, Lin CW, Wang CC, Su WW, Hsieh TY, Lin CL, Tsai WL, Lee TH, Chen GY, Wang SJ, Chang CC, Yang SS, Wu WC, Huang CS, Chou KH, Kao CN, Tsai PC, Liu CH, Lee MH, Cheng CY, Tsai MC, Liu CJ, Dai CY, Lin HC, Kao JH, Chuang WL, **Yu ML\***; TACR investigators. 2022. Sofosbuvir/Velpatasvir for Hepatitis C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan. *Infect Dis Ther*. 2022 Feb;11(1):485-500. Epub 2021 Dec 28. PMID: 34967920. (2020, IF: 5.322, Infectious Diseases: 16/93= 17.20%)
  20. Hsu PY, Cheng TS, Chuang SC, Chang WT, Liang PC, Hsu CT, Wei YJ, Jang TY, Yeh ML, Huang CI, Lin YH, Wang CW, Hsieh MY, Hou NJ, Hsieh MH, Tsai YS, Ko YM, Lin CC, Chen KY, Dai CY, Lin ZY, Chen SC, Huang JF, Chuang WL, Huang CF\*, **Yu ML\***. 2022. Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha-fetoprotein levels. *Cancer Med*. 2022 Jan;11(1):104-116. Epub 2021 Nov 16. PMID: 34786871. (2020, IF: 4.452, Oncology: 108/242=44.63%)
  21. Chen YC, Chang TS, Chen CH, Cheng PN, Lo CC, Mo LR, Chen CT, Huang CF, Kuo HT, Huang YH, Tai CM, Peng CY, Bair MJ, Yeh ML, Lin CL, Lin CY, Lee PL, Chong LW, Hung CH, Huang JF, Yang CC, Hu JT, Lin CW, Wang CC, Su WW, Hsieh TY, Lin CL, Tsai WL, Lee TH, Chen GY, Wang SJ, Chang CC, Yang SS, Wu WC, Huang CS, Hsiung CK, Kao CN, Tsai PC, Liu CH, Lee MH, Dai CY, Kao JH, Chuang WL, Lin HC, Chen CY, Tseng KC\*, **Yu ML\***,

On Behalf Of TACR Investigators. **2022**. Factors Associated with Significant Platelet Count Improvement in Thrombocytopenic Chronic Hepatitis C Patients Receiving Direct-Acting Antivirals. *Viruses*. 2022 Feb 7;14(2):333. PMID: 35215926; PMCID: PMC8879038. (2020, IF: 5.048, Virology : 10/37=27.03%)

## 2022 Co-author

22. Lazarus JV\*, Mark HE, Anstee OM, Arab JP, Batterham RL, Castera L, Cortez-Pinto H, Crespo J, Cusi K, Dirac MA, Francque S, George J, Hagström H, Huang TT, Ismail MH, Kautz A, Sarin SK, Loomba R, Miller V, Newsome PN, Ninburg M, Ocama P, Ratziu V, Rinella M, Romero D, Romero-Gómez M, Schattenberg JM, Tsochatzis EA, Valenti L, Wong VW, Yilmaz Y, Younossi ZM, Zelber-Sagi S; **NAFLD Consensus Consortium**. **2022**. Advancing the global public health agenda for NAFLD: a consensus statement. *Nat Rev Gastroenterol Hepatol*. 2022 Jan;19(1):60-78. Epub 2021 Oct 27. PMID: 34707258. (2020, IF: 46.802, *Gastroenterology & Hepatology*: 1/92=1.09%)
23. Sapena V, Enea M, Torres F, Celsa C, Rios J, Rizzo GEM, Nahon P, Mariño Z, Tateishi R, Minami T, Sangiovanni A, Fornis X, Toyoda H, Brillanti S, Conti F, Degasperi E, **Yu ML**, Tsai PC, Jean K, El Kassas M, Shousha HI, Omar A, Zavaglia C, Nagata H, Nakagawa M, Asahina Y, Singal AG, Murphy C, Kohla M, Masetti C, Dufour JF, Merchante N, Cavalletto L, Chemello LL, Pol S, Crespo J, Calleja JL, Villani R, Serviddio G, Zanetto A, Shalaby S, Russo FP, Bielen R, Trevisani F, Cammà C, Bruix J, Cabibbo G\*, Reig M\*. **2022**. Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis. *Gut*. 2022 Mar;71(3):593-604. Epub 2021 Mar 19. PMID: 33741640. (2020, IF: 23.059, *Gastroenterology & Hepatology*: 3/92=3.26%)
24. Dai CY\*, Huang JF, Chuang WL, **Yu ML**. **2022**. DAA Therapy in Hepatitis C in Patients With Chronic Kidney Disease: New Information for GFR Category G4 and G5. *Clin Gastroenterol Hepatol*. 2022 Jan;20(1):246-247. Epub 2020 Nov 26. PMID: 33248105. (2020, IF: 11.382, *Gastroenterology & Hepatology*: 8/92=8.70%)
25. Park J, Le AK, Tseng TC, Yeh ML, Jun DW, Trinh H, Wong GL, Chen CH, Peng CY, Kim SE, Oh H, Kwak MS, Cheung KS, Toyoda H, Hsu YC, Jeong JY, Yoon EL, Ungtrakul T, Zhang J, Xie O, Ahn SB, Enomoto M, Shim JJ, Cunningham C, Jeong SW, Cho YK, Ogawa E, Huang R, Lee DH, Takahashi H, Tsai PC, Huang CF, Dai CY, Tseng CH, Yasuda S, Kozuka R, Li J, Wong C, Wong CC, Zhao C, Hoang J, Eguchi Y, Wu C, Tanaka Y, Gane E, Tanwandee T, Cheung R, Yuen MF, Lee HS, **Yu ML**, Kao JH, Yang HI, Nguyen MH\*. **2022**. Progression Rates by Age, Sex, Treatment, and Disease Activity by AASLD and EASL Criteria: Data for Precision Medicine. *Clin Gastroenterol Hepatol* 2022 Apr;20(4):874-885.e4. doi: 10.1016/j.cgh.2021.05.062. Epub 2021 Jun 2. PMID: 34089852. (2020, IF: 11.382, *Gastroenterology & Hepatology*: 8/92=8.70%)
26. Younossi ZM, Ong JP, Takahashi H, Yilmaz Y, Eguc Hi Y, El Kassas M, Buti M, Diago M, Zheng MH, Fan JG, **Yu ML**, Wai-Sun Wong V, Alswat K, Chan WK, Mendez-Sanchez N, Burra P, Bugianesi E, Duseja AK, George J, Papatheodoridis GV, Saeed H, Castera L, Arrese M, Kugelmas M, Romero-Gomez M, Alqahtani S, Ziayee M, Lam B, Younossi I, Racila A, Henry L, Stepanova M; Global Nonalcoholic Steatohepatitis Council. **2022**. A Global Survey of Physicians Knowledge About Nonalcoholic Fatty Liver Disease. *Clin Gastroenterol Hepatol*. 2022 Jun;20(6):e1456-e1468. doi: 10.1016/j.cgh.2021.06.048. Epub 2021 Jul 3. PMID: 34229038. (2020, IF: 11.382, *Gastroenterology & Hepatology*: 8/92=8.70%)
27. Mak LY, Hoang J, Jun DW, Chen CH, Peng CY, Yeh ML, Kim SE, Huang DO, Jeong JY, Yoon E, Oh H, Tsai PC, Huang CF, Ahn SB, Trinh H, Xie O, Wong GLH, Enomoto M, Shim JJ, Lee DH, Liu L, Kozuka R, Cho YK, Jeong SW, Kim HS, Trinh L, Dao A, Huang R, Hui RW, Tsui V, Ouek S, Khine HHTW, Ogawa E, Dai CY, Huang JF, Cheung R, Wu C, Chuang WL, Lim SG, **Yu ML**, Yuen MF\*, Nguyen MH\*. **2022**. Longitudinal renal changes in chronic hepatitis B patients treated with entecavir versus TDF: a REAL-B study. *Hepatol Int*. 2022 Feb;16(1):48-58. Epub 2021 Nov 25. PMID: 34822056. (2020, IF: 6.047, *Gastroenterology & Hepatology*: 24/92=26.09%)
28. Lau G\*, **Yu ML**, Wong G, Thompson A. **2022**. Are immune-checkpoint inhibitors immunosuppressive to hepatitis B virus? *Hepatol Int*. 2022 Apr;16(2):482-483. doi: 10.1007/s12072-022-10318-7. Epub 2022 Mar 1. PMID: 35229274. (2020, IF: 6.047, *Gastroenterology & Hepatology*: 24/92=26.09%)
29. Lin MC, Dai CY, Huang CF, Yeh ML, Liu YC, Hsu PY, Wei YJ, Lee PL\*, Huang CI, Liang PC, Hsieh MY, Hsieh MH, Jang TY, Lin ZY, Huang JF\*, **Yu ML**, Chuang WL. **2022**. Itemization difference of patient-reported outcome in patients with chronic liver disease. *PLoS One*. 2022

- Feb 22;17(2):e0264348. PMID: 35192675. (2020, IF: 3.24, Multidisciplinary sciences: 26/72=36.11%)
30. Batsaikhan B, Huang CI, Yeh ML, Huang CF, Lin YH, Liang PC, Hsieh MY, Lin YC, Huang JF, Chuang WL, Lee JC, **Yu ML**, Kuo HT\*, Dai CY\*. Persistent crvoglobulinemia after antiviral treatment is associated with advanced fibrosis in chronic hepatitis C patients. *PLoS One*. 2022 May 13;17(5):e0268180. doi: 10.1371/journal.pone.0268180. PMID: 35560166; PMCID: PMC9106159. (2020, IF: 3.24, Multidisciplinary sciences: 26/72=36.11%)
31. Lin ZY\*, Yeh ML, Huang CI, Chen SC, Huang CF, Huang JF, Dai CY, **Yu ML**, Chuang WL. 2022. Limited sorafenib anticancer effects on primary cultured hepatocellular carcinoma cells with high NANOG expression. *Kaohsiung J Med Sci*. 2022 Feb;38(2):157-164. Epub 2021 Nov 16. PMID: 35142429. (2020, IF: 2.744, Medicine, Research & Experimental: 93/140=66.43%)
32. Méndez-Sánchez N, Bugianesi E, Gish RG, Lammert F, Tilg H, Nguyen MH, Sarin SK, Fabrellas N, Zelber-Sagi S, Fan JG, Shiha G, Targher G, Zheng MH, Chan WK, Vinker S, Kawaguchi T, Castera L, Yilmaz Y, Koreniak M, Spearman CW, Ungan M, Palmer M, El-Shabrawi M, Gruss HJ, Dufour JF, Dhawan A, Wedemeyer H, George J, Valenti L, Fouad Y, Romero-Gomez M, Eslam M: **Global multi-stakeholder consensus on the redefinition of fatty liver disease**. 2022. Global multi-stakeholder endorsement of the MAFLD definition. *Lancet Gastroenterol Hepatol*. 2022 May;7(5):388-390. doi: 10.1016/S2468-1253(22)00062-0. Epub 2022 Mar 3. PMID: 35248211. (2020, IF: 18.486, Gastroenterology & Hepatology: 5/92=5.43%)
33. Jang TY, Huang CF, Yeh ML, Huang CI\*, Dai CY, Tsai PC, Hsu PY, Wei YJ, Hou NJ, Liang PC, Lin YH, Wang CW, Hsieh MY, Lin ZY, Huang JF\*, **Yu ML**, Chuang WL. 2022. Serum *Wisteria floribunda* agglutinin-positive Mac-2-binding protein expression predicts disease severity in nonalcoholic steatohepatitis patients. *Kaohsiung J Med Sci*. 2022 Mar;38(3):261-267. doi: 10.1002/kjm2.12474. Epub 2021 Nov 16. PMID: 34786828. (2020, IF: 2.744, Medicine, Research & Experimental: 93/140=66.43%)

#### 2021 First Author or Corresponding Author

34. Huang CF, Wei YJ, Wu YT, Chiu YW, **Yu ML**\*. 2021. Real world experience of serial serum levels of GS-331007 in chronic hepatitis C hemodialysis patients during and after sofosbuvir/velpatasvir therapy. *J Hepatol*. 2021 Oct;75(4):1006-1007. Epub 2021 May 26. PMID: 34051333. (2020, IF: 25.083, Gastroenterology & Hepatology: 2/92=2.17%)
35. Dai CY, Chuang WL, **Yu ML**\*. 2021. EASL recommendations on treatment of hepatitis C: Final update of the series - Some issues. *J Hepatol*. 2021 Feb;74(2):473-474. PMID: 33223214. (2020, IF: 25.083, Gastroenterology & Hepatology: 2/92=2.17%)
36. **Yu ML**\*, Huang CF, Wei YJ, Lin WY, Lin YH, Hsu PY, Hsu CT, Liu TW, Lee JJ, Niu SW, Huang JC, Hung TS, Yeh ML, Huang CI, Liang PC, Hsieh MY, Chen SC, Huang JF, Chang JM, Chiu YW, Dai CY, Hwang SJ, Chuang WL\*; FORMOSA-LIKE investigators. 2021. Establishment of an outreach, grouping healthcare system to achieve microelimination of HCV for uremic patients in haemodialysis centres (ERASE-C). *Gut*. 2021 Dec;70(12):2349-2358. Epub 2020 Dec 10. PMID: 33303567. (2020, IF: 23.059, Gastroenterology & Hepatology: 3/92=3.26%)
37. Yeh ML, Liang PC, Tsai PC, Wang SC, Leong J, Ogawa E, Jun DW, Tseng CH, Landis C, Tanaka Y, Huang CF, Hayashi J, Hsu YC, Huang JF, Dai CY, Chuang WL, Nguyen MH\*, **Yu ML**\*. 2021. Characteristics and Survival Outcomes of Hepatocellular Carcinoma Developed after HCV SVR. *Cancers (Basel)*. 2021 Jul 9;13(14):3455. PMID: 34298669; PMCID: PMC8306695. (2020, IF: 6.639, Oncology: 51/242= 21.07%)
38. Lin CC, Liu TW, Yeh ML, Tsai YS, Tsai PC, Huang CF, Huang JF, Chuang WL, Dai CY\*, **Yu ML**\*. 2021. Significant down-regulation of growth hormone receptor expression revealed as a new unfavorable prognostic factor in hepatitis C virus-related hepatocellular carcinoma. *Clin Mol Hepatol*. 2021 Apr;27(2):313-328. PMID: 33317258; PMCID: PMC8046631. (2020, IF: 6.074, Gastroenterology & Hepatology: 23/92=25%)
39. Huang CF, Wu PF, Yeh ML, Huang CI, Liang PC, Hsu CT, Hsu PY, Liu HY, Huang YC, Lin ZY, Chen SC, Huang JF, Dai CY, Chuang WL, **Yu ML**\*. 2021. Scaling up the in-hospital hepatitis C virus care cascade in Taiwan. *Clin Mol Hepatol*. 2021 Jan;27(1):136-143. PMID: 33317253; PMCID: PMC7820217. (2020, IF: 6.074, Gastroenterology & Hepatology: 23/92=25%)
40. Hsu PY, Wei YJ, Lee JJ, Niu SW, Huang JC, Hsu CT, Jang TY, Yeh ML, Huang CI, Liang PC, Lin YH, Hsieh MY, Hsieh MH, Chen SC, Dai CY, Lin ZY, Chen SC, Huang JF, Chang JM, Hwang SJ, Chuang WL, Huang CF, Chiu YW\*, **Yu ML**\*. 2021. Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis. *Clin Mol Hepatol*. 2021 Jan;27(1):186-196. PMID: 33317251; PMCID: PMC7820195. (2020, IF: 6.074, Gastroenterology & Hepatology: 23/92=25%)
41. Lau G\*, **Yu ML**\*, Wong G, Thompson A, Ghazinian H, Hou JL, Piratvisuth T, Jia JD,

- Mizokami M, Cheng G, Chen GF, Liu ZW, Baatarkhuu O, Cheng AL, Ng WL, Lau P, Mok T, Chang JM, Hamid S, Dokmeci AK, Gani RA, Payawal DA, Chow P, Park JW, Strasser SI, Mohamed R, Win KM, Tawesak T, Sarin SK, Omata M. **2021**. APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy. *Hepatol Int*. 2021 Aug 24;1–18. Epub ahead of print. PMID: 34427860; PMCID: PMC8382940. **(2020, IF: 6.047, Gastroenterology & Hepatology: 24/92=26.09%)**
42. Lin CW, Chen YS, Lo GH, Wu TC, Yeh JH, Yeh ML, Dai CY, Huang JF, Chuang WL, Roberts L, Jun DW, Toyoda H, Yasuda S, Nguyen MH, **Yu ML\***. **2021**. Resubclassification and clinical management for Barcelona Clinic Liver Cancer Stage C hepatocellular carcinoma. *Hepatol Int*. 2021 Aug;15(4):946-956. Epub 2021 May 18. PMID: 34008091. **(2020, IF: 6.047, Gastroenterology & Hepatology: 24/92=26.09%)**
43. Huang JF, Dai CY, Huang CF, Tsai PC, Yeh ML, Hsu PY, Huang SF, Bair MJ, Hou NJ, Huang CI, Liang PC, Lin YH, Wang CW, Hsieh MY, Chen SC, Lin ZY, **Yu ML\***, Chuang WL\*. **2021**. First-in-Asian double-blind randomized trial to assess the efficacy and safety of insulin sensitizer in nonalcoholic steatohepatitis patients. *Hepatol Int*. 2021 Oct;15(5):1136-1147. Epub 2021 Aug 12. PMID: 34386935. **(2020, IF: 6.047, Gastroenterology & Hepatology: 24/92=26.09%)**
44. Yeh ML, Hung CH, Tseng KC, Lai HC, Chen CY, Kuo HT, Wang JH, Chen JJ, Lee PL, Chien RN, Yang CC, Lo GH, Tai CM, Lin CW, Kao JH, Liu CH, Yan SL, Bair MJ, Lin CY, Su WW, Chu CH, Chen CJ, Tung SY, Lo CC, Cheng PN, Chiu YC, Wang CC, Cheng JS, Tsai WL, Lin HC, Huang YH, Huang CF, Huang JF, Dai CY, Chuang WL, Tsai PC, Peng CY, Liu CJ\*, **Yu ML\***. **2021** Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH). *Hepatol Int*. 2021 Oct;15(5):1109-1121. Epub 2021 Aug 7. PMID: 34365587. **(2020, IF: 6.047, Gastroenterology & Hepatology: 24/92=26.09%)**
45. Chen CY, Huang CF, Cheng PN, Tseng KC, Lo CC, Kuo HT, Huang YH, Tai CM, Peng CY, Bair MJ, Chen CH, Yeh ML, Lin CL, Lin CY, Lee PL, Chong LW, Hung CH, Huang JF, Yang CC, Hu JT, Lin CW, Chen CT, Wang CC, Su WW, Hsieh TY, Lin CL, Tsai WL, Lee TH, Chen GY, Wang SJ, Chang CC, Mo LR, Yang SS, Wu WC, Huang CS, Hsiung CK, Kao CN, Tsai PC, Liu CH, Lee MH, Liu CJ, Dai CY, Kao JH, Chuang WL, Lin HC, **Yu ML\***. **2021**. Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan. *Liver Int*. 2021 Jun;41(6):1265-1277. PMID: 33655714. **(2020, IF: 5.828, Gastroenterology & Hepatology: 25/92=27.17)**
46. Wang SC, Li CY, Chang WT, Cheng WC, Yen CH, Tu WY, Lin ZY, Lin CC, Yeh ML, Huang CF, Huang JF, Dai CY, Chuang WL, Chen YL, **Yu ML\***. **2021**. Exosome-derived differentiation antagonizing non-protein coding RNA with risk of hepatitis C virus-related hepatocellular carcinoma recurrence. *Liver Int*. 2021 May;41(5):956-968. PMID: 33346937. **(2020, IF: 5.828, Gastroenterology & Hepatology: 25/92=27.17)**
47. Wang SJ, Huang CF, **Yu ML\***. **2021**. Elbasvir and grazoprevir for the treatment of hepatitis C. *Expert Rev Anti Infect Ther*. 2021 Sep;19(9):1071-1081. Epub 2021 Jan 17. PMID: 33428488. **(2020, IF: 5.091, Pharmacology & Pharmacy: 61/276= 22.10%)**
48. Hong CM, Lin YY, Liu CJ, Lai YY, Yeh SH, Yang HC, Kao JH, Hsu SJ, Huang YH, Yang SS, Kuo HT, Cheng PN, **Yu ML\***, Chen PJ\*. **2021** Drug Resistance Profile and Clinical Features for Hepatitis C Patients Experiencing DAA Failure in Taiwan. *Viruses*. 2021 Nov 17;13(11):2294. PMID: 34835100. **(2020, IF: 5.048, Virology : 10/37=27.03%)**
49. Lu MY, Chen CT, Shih YL, Tsai PC, Hsieh MH, Huang CF, Yeh ML, Huang CI, Wang SC, Tsai YS, Ko YM, Lin CC, Chen KY, Wei YJ, Hsu PY, Hsu CT, Jang TY, Liu TW, Liang PC, Hsieh MY, Lin ZY, Chen SC, Huang JF, Dai CY, Chuang WL, **Yu ML\***, Chang WY. **2021**. Changing epidemiology and viral interplay of hepatitis B, C and D among injecting drug user-dominant prisoners in Taiwan. *Sci Rep*. 2021 Apr 20;11(1):8554. PMID: 33879825; PMCID: PMC8058093. **(2020, IF: 4.38, Multidisciplinary sciences: 17/72=23.61%)**
50. Jang TY, Wei YJ, Liu TW, Yeh ML, Liu SF, Hsu CT, Hsu PY, Lin YH, Liang PC, Hsieh MH, Ko YM, Tsai YS, Chen KY, Lin CC, Tsai PC, Wang SC, Huang CI, Lin ZY, Chen SC, Chuang WL, Huang JF, Dai CY, Huang CF,\* **Yu ML\***. **2021**. Role of hepatitis D virus infection in development of hepatocellular carcinoma among chronic hepatitis B patients treated with nucleotide/nucleoside analogues. *Sci Rep*. 2021 Apr 14;11(1):8184. PMID: 33854160; PMCID: PMC8047028. **(2020, IF: 4.38, Multidisciplinary sciences: 17/72=23.61%)**
51. Huang CF, Kuo HT, Chang TS, Lo CC, Hung CH, Huang CW, Chong LW, Cheng PN, Yeh ML, Peng CY, Cheng CY, Huang JF, Bair MJ, Lin CL, Yang CC, Wang SJ, Hsieh TY, Lee TH, Lee PL, Wu WC, Lin CL, Su WW, Yang SS, Wang CC, Hu JT, Mo LR, Chen CT, Huang YH, Chang CC, Huang CS, Chen GY, Kao CN, Tai CM, Liu CJ, Lee MH, Tsai PC, Dai CY, Kao JH,

- Lin HC, Chuang WL, Chen CY, Tseng KC\*, **Yu ML\***. 2021 Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan. *Sci Rep*. 2021 Dec 6;11(1):23473. PMID: 34873250; PMCID: PMC8648748. (2020, IF: 4.38, Multidisciplinary sciences: 17/72=23.61%)
52. Hsieh MH, Bair MJ, Tsai PC, Tseng KC, Lo CC, Chen CY, Kuo HT, Hung CH, Lai HC, Peng CY, Wang JH, Chen JJ, Lee PL, Chien RN, Yang CC, Lo GH, Kao JH, Liu CJ, Liu CH, Yan SL, Lin CY, Su WW, Chu CH, Chen CJ, Tung SY, Tai CM, Lin CW, Cheng PN, Chiu YC, Wang CC, Cheng JS, Tsai WL, Lin HC, Huang YH, Yeh ML, Huang CF, Huang JF, Dai CY, **Yu ML\***, Chuang WL; T-COACH investigators. 2021. Long-term risk of end stage renal diseases with maintenance dialysis among chronic hepatitis C patients after antiviral therapy in Taiwan. *J Gastroenterol Hepatol*. 2021 Aug;36(8):2247-2254. Epub 2021 Mar 30. PMID: 33624849. (2020, IF: 4.029, Gastroenterology & Hepatology: 45/92=48.91%)
53. Hsu WF, Tsai PC, Chen CY, Tseng KC, Lai HC, Kuo HT, Hung CH, Tung SY, Wang JH, Chen JJ, Lee PL, Chien RN, Lin CY, Yang CC, Lo GH, Tai CM, Lin CW, Kao JH, Liu CJ, Liu CH, Yan SL, Bair MJ, Su WW, Chu CH, Chen CJ, Lo CC, Cheng PN, Chiu YC, Wang CC, Cheng JS, Tsai WL, Lin HC, Huang YH, Huang JF, Dai CY, Chuang WL, **Yu ML\***, Peng CY\*. 2021. Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (Taiwanese chronic hepatitis C cohort). *J Gastroenterol Hepatol*. 2021 Oct;36(10):2884-2892. Epub 2021 May 21. PMID: 33963615. (2020, IF: 4.029, Gastroenterology & Hepatology: 45/92=48.91%)
54. Yeh ML, Liang PC, Huang CI, Hsieh MH, Lin YH, Jang TY, Wei YJ, Hsu PY, Hsu CT, Wang CW, Hsieh MY, Lin ZY, Chen SC, Huang CF, Huang JF, Dai CY, Chuang WL, **Yu ML\***. 2021. Seroreversion of hepatitis B surface antigen among subjects with resolved hepatitis B virus infection: A community-based cohort study. *J Gastroenterol Hepatol*. 2021 Nov;36(11):3239-3246. Epub 2021 Aug 8. PMID: 34318943. (2020, IF: 4.029, Gastroenterology & Hepatology: 45/92=48.91%)
55. Wei YJ, Hsu PY, Lee JJ, Niu SW, Huang JC, Hsu CT, Jang TY, Yeh ML, Huang CI, Liang PC, Lin YH, Hsieh MY, Hsieh MH, Chen SC, Dai CY, Lin ZY, Chen SC, Huang JF, Chang JM, Hwang SJ, Chuang WL, Huang CF, Chiu YW, **Yu ML\***. 2021. Evolutionary seroepidemiology of viral hepatitis and the gap in hepatitis C care cascades among uraemic patients receiving haemodialysis in Taiwan-the Formosa-Like Group. *J Viral Hepat*. 2021 May;28(5):719-727. PMID: 33533547. (2020, IF: 3.728, Infectious diseases: 41/93=44.09%)
56. **Yu ML**, Kao JH. 2021. Reply to "Tacrolimus concentrations were not affected by glecaprevir/pibrentasvir treatment for hepatitis C virus infection in an adult living donor liver transplant recipient with uremia". *J Formos Med Assoc*. 2021 Jun;120(6):1410-1411. PMID: 33422401. (2020, IF: 3.282, Medicine, General & Internal: 53/167=31.74%)
57. Jang TY, Wei YJ, Yeh ML, Liu SF, Hsu CT, Hsu PY, Liu TW, Lin YH, Liang PC, Hsieh MH, Ko YM, Tsai YS, Chen KY, Lin CC, Tsai PC, Wang SC, Huang CI, Lin ZY, Chen SC, Chuang WL, Huang JF, Dai CY, Huang CF\*, **Yu ML\***. 2021. Role of hepatitis D virus in persistent alanine aminotransferase abnormality among chronic hepatitis B patients treated with nucleotide/nucleoside analogues. *J Formos Med Assoc*. 2021 Jan;120(1 Pt 2):303-310. Epub 2020 Oct 24. PMID: 33109431. (2020, IF: 3.282, Medicine, General & Internal: 53/167=31.74%)
58. **Yu ML**, Tsai WL, Chu CJ, Kao JH. 2021. Characteristics of patients with hepatitis C virus infection and antiviral treatment initiation in Taiwan: The MOSAIC study. *Kaohsiung J Med Sci*. 2021 Mar;37(3):245-252. PMID: 33089964. (2020, IF: 2.744, Medicine, Research & Experimental: 93/140=66.43%)
59. Yeh ML, Kuo HT, Huang CI, Huang CF, Hsieh MY, Liang PC, Lin IH, Hsieh MH, Lin ZY, Chen SC, Dai CY, Huang JF, **Yu ML\***, Chuang WL. 2021. Eradication of hepatitis C virus preserve liver function and prolong survival in advanced hepatocellular carcinoma patients with limited life expectancy. *Kaohsiung J Med Sci*. 2021 Feb;37(2):145-153. PMID: 33022892. (2020, IF: 2.744, Medicine, Research & Experimental: 93/140=66.43%)
60. **Yu ML**, Chuang WL\*. 2021. Path from the discovery to the elimination of hepatitis C virus: Honoring the winners of the Nobel Prize in Physiology or Medicine 2020. *Kaohsiung J Med Sci*. 2021 Jan;37(1):7-11. Epub 2020 Dec 18. PMID: 33337581. (2020, IF: 2.744, Medicine, Research & Experimental: 93/140=66.43%)

### 2021 Co-author

61. Klionsky DJ, et al. **Yu ML**, et al. 2021. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)<sup>1</sup>. *Autophagy*. 2021 Jan;17(1):1-382. PMID: 33634751; PMCID: PMC7996087. (2020, IF: 16.016, Cell Biology: 14/195=7.18%)
62. Siphepho PY, Liu YT, Shabangu CS, Huang JF, Huang CF, Yeh ML, **Yu ML**, Wang SC. 2021.



The Impact of Steatosis on Chronic Hepatitis C Progression and Response to Antiviral Treatments. *Biomedicines*. 2021 Oct 17;9(10):1491. PMID: 34680608; PMCID: PMC8533513. (2020, IF: 6.081, Pharmacology & Pharmacy: 33/276=11.96%)

63. Shabangu CS, Siphepho PY, Li CY, Cheng WC, Lu MY, Huang CF, Yeh ML, Dai CY, Huang JF, Chuang WL, Lin ZY, **Yu ML**, Wang SC\*. 2021. The Persistence of Hepatitis C Virus Infection in Hepatocytes Promotes Hepatocellular Carcinoma Progression by Pro-Inflammatory Interleukin-8 Expression. *Biomedicines*. 2021 Oct 11;9(10):1446. PMID: 34680563; PMCID: PMC8533125. (2020, IF: 6.081, Pharmacology & Pharmacy: 33/276=11.96%)
64. Liu M, Tseng TC, Jun DW, Yeh ML, Trinh H, Wong GLH, Chen CH, Peng CY, Kim SE, Oh H, Kwak MS, Cheung M, Toyoda H, Hsu YC, Jeong JY, Yoon EL, Ungtrakul T, Zhang J, Xie O, Ahn SB, Enomoto M, Shim JJ, Cunningham C, Jeong SW, Cho YK, Ogawa E, Huang R, Lee DH, Takahashi H, Tsai PC, Huang CF, Dai CY, Tseng CH, Yasuda S, Kozuka R, Li J, Wong C, Wong CC, Zhao C, Hoang J, Eguchi Y, Wu C, Tanaka Y, Gane E, Tanwandee T, Cheung R, Yuen MF, Lee HS, **Yu ML**, Kao JH, Yang HI, Nguyen MH\*. 2021. Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patients. *Hepatol Int*. 2021 Feb;15(1):71-81. PMID: 33394321. (2020, IF: 6.047, Gastroenterology & Hepatology: 24/92=26.09%)
65. Teng W, Chang TT, Yang HI, Peng CY, Su CW, Su TH, Hu TH, **Yu ML**, Yang HC, Wu JC\*. 2021. Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines. *Hepatol Int*. 2021 Dec;15(6):1421-1430. Epub 2021 Nov 6. PMID: 34741723. (2020, IF: 6.047, Gastroenterology & Hepatology: 24/92=26.09%)
66. Le AK, Yang HI, Yeh ML, Jin M, Trinh HN, Henry L, Liu A, Zhang JO, Li J, Wong C, Wong C, Cheung R, **Yu ML**, Nguyen MH\*. 2021. Development and Validation of a Risk Score for Liver Cirrhosis Prediction in Untreated and Treated Chronic Hepatitis B. *J Infect Dis*. 2021 Jan 4;223(1):139-146. PMID: 32525978. (2020, IF: 5.226, Infectious Diseases: 18/93= 19.35%)
67. Li J, Yang HI, Yeh ML, Le MH, Le AK, Yeo YH, Dai CY, Barnett S, Zhang JO, Huang JF, Trinh HN, Wong C, Wong C, Hoang JK, Cheung R, **Yu ML**, Nguyen MH\*. 2021. Association Between Fatty Liver and Cirrhosis, Hepatocellular Carcinoma, and Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B. *J Infect Dis*. 2021 Jul 15;224(2):294-302. PMID: 33249474. (2020, IF: 5.226, Infectious Diseases: 18/93= 19.35%)
68. Hsu YC, Yeh ML, Wong GL, Chen CH, Peng CY, Buti M, Enomoto M, Xie Q, Trinh H, Preda C, Liu L, Cheung KS, Yeo YH, Hoang J, Huang CF, Riveiro-Barciela M, Kozuka R, Istratescu D, Tsai PC, Accarino EV, Lee DH, Wu JL, Huang JF, Dai CY, Cheung R, Chuang WL, Yuen MF, Wong VW, **Yu ML**, Nguyen MH\*. 2021. Incidences and Determinants of Functional Cure during Entecavir or Tenofovir Disoproxil Fumarate for Chronic Hepatitis B. *J Infect Dis*. 2021 Dec 1;224(11):1890-1899. PMID: 33999179. (2020, IF: 5.226, Infectious Diseases: 18/93= 19.35%)
69. Tsai YF, Liu YC, Yang CI, Chuang TM, Ke YL, Yeh TJ, Gau YC, Du JS, Wang HC, Cho SF, Hsu CM, Wu PF, Huang CI, Huang CF, **Yu ML**, Dai CY, Hsiao HH\*. 2021. Poor Prognosis of Diffuse Large B-Cell Lymphoma with Hepatitis C Infection. *J Pers Med*. 2021 Aug 27;11(9):844. PMID: 34575621. (2020, IF: 4.945, Health Care Sciences & Services: 15/107=14.02%)
70. Cheng PN, Chen CY, **Yu ML**, Lin CC, Lin CY, Peng CY, Tseng KC, Lo CC, Tseng IH, Liu CJ\*. 2021. Elbasvir/grazoprevir is effective and tolerable for the treatment of HCV GT1-infected patients: A real world multicenter observatory study in Taiwan. *J Microbiol Immunol Infect*. 2021 Aug;54(4):588-595. Epub 2020 May 22. PMID: 32499107. (2020, IF: 4.399, Infectious Diseases: 27/93=29.03%)
71. Hsu PY, Wei YJ, Liang PC, Lee JJ, Niu SW, Huang JC, Hsu CT, Jang TY, Huang CI, Lin YH, Hsieh MY, Hsieh MH, Chen SC, Dai CY, Lin ZY, Chen SC, Huang JF, Chang JM, Yeh ML\*, Huang CF, Chiu YW, Hwang SJ, Chuang WL, **Yu ML**. 2021. Comorbidities in patients with chronic hepatitis C and hepatitis B on hemodialysis. *J Gastroenterol Hepatol*. 2021 Aug;36(8):2261-2269. Epub 2021 Mar 10. PMID: 33651428. (2020, IF: 4.029, Gastroenterology & Hepatology: 45/92=48.91%)
72. Polaris Observatory Collaborators. 2021. The case for simplifying and using absolute targets for viral hepatitis elimination goals. *J Viral Hepat*. 2021 Jan;28(1):12-19. Epub 2020 Nov 4. PMID: 32979881. (2020, IF: 3.728, Infectious diseases: 41/93=44.09%)
73. Joseph K, Shabangu CS, Jang TY, Huang CF, Dai CY, Huang JF, Chuang WL, **Yu ML**, Wang SC\*. 2021. The Prevalence and Serological Association of Hepatitis D Virus Genotypes in Taiwan. *Pathogens*. 2021 Sep 23;10(10):1227. PMID: 34684176. (2020, IF: 3.492, Microbiology: 67/136= 49.26%)
74. Hsu SJ, **Yu ML**, Su CW, Peng CY, Chien RN, Lin HH, Lo GH, Su WW, Kuo HT, Hsu CW, Yang SS, Yang SS, Tseng KC, Qin A, Huang YW, Chuang WL\*. 2021. Ropeginterferon

- Alfa-2b administered every two weeks for patients with genotype 2 chronic hepatitis C. *J Formos Med Assoc.* 2021 Mar;120(3):956-964. Epub 2020 Oct 16. PMID: 33077341. **(2020, IF: 3.282, Medicine, General & Internal: 53/167=31.74%)**
75. Lin CP, Liang PC, Huang CI, Yeh ML, Hsu PY, Hsu CT, Wei YJ, Liu TW, Hsieh MY, Hou NJ, Jang TY, Lin YH, Wang CW, Lin ZY, Chen SC, Huang CF\*, Huang JF, Dai CY, Chuang WL, **Yu ML**. 2021. Concordance of SVR12, SVR24 and SVR durability in Taiwanese chronic hepatitis C patients with direct-acting antivirals. *PLoS One.* 2021 Feb 4;16(2):e0245479. PMID: 33539408; PMCID: PMC7861540. **(2020, IF: 3.24, Multidisciplinary sciences: 26/72=36.11%)**
76. Huang YC, Huang CF, Liu SF, Liu HY, Yeh ML, Huang CI, Hsieh MH, Dai CY, Chen SC, **Yu ML**, Chuang WL, Huang JF\*. 2021. The performance of HCV GT plus RUO reagent in determining Hepatitis C virus genotypes in Taiwan. *PLoS One.* 2021 Jan 29;16(1):e0246376. PMID: 33513184; PMCID: PMC7845948. **(2020, IF: 3.24, Multidisciplinary sciences: 26/72=36.11%)**
77. Liu HY, Lin YH, Lin PJ, Tsai PC, Liu SF, Huang YC, Tsai JJ, Huang CI, Yeh ML, Liang PC, Lin ZY, Dai CY, Huang JF, Chuang WL, Huang CF\*, **Yu ML**. 2021. Anti-HCV antibody titer highly predicts HCV viremia in patients with hepatitis B virus dual-infection. *PLoS One.* 2021 Jul 1;16(7):e0254028. PMID: 34197557. **(2020, IF: 3.24, Multidisciplinary sciences: 26/72=36.11%)**
78. Lin ZY\*, Yeh ML, Huang CI, Chen SC, Huang CF, Huang JF, Dai CY, **Yu ML**, Chuang WL. 2021. Potential of novel colchicine dosage schedule for the palliative treatment of advanced hepatocellular carcinoma. *Kaohsiung J Med Sci.* 2021 Jul;37(7):616-623. Epub 2021 Mar 3. PMID: 33655688. **(2020, IF: 2.744, Medicine, Research & Experimental: 93/140=66.43%)**
79. Cheng TS, Liang PC, Huang CF, Yeh ML, Huang CI, Lin ZY, Chen SC, Huang JF, Dai CY\*, Hsieh PH\*, Chuang WL, **Yu ML**. 2021. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment. *Kaohsiung J Med Sci.* 2021 Apr;37(4):334-345. Epub 2020 Nov 5. PMID: 33151016. **(2020, IF: 2.744, Medicine, Research & Experimental: 93/140=66.43%)**
80. Jang TY, Liang PC, Liu TW, Wei YJ, Yeh ML, Hsu CT, Hsu PY, Lin YH, Hsieh MH, Huang CI, Huang CF, Lin ZY, Chen SC, Huang JF, Dai CY\*, **Yu ML**, Chuang WL. 2021. Genotype distribution, clinical characteristics, and racial differences observed in chronic hepatitis C patients in Pingtung, Taiwan. *J Chin Med Assoc.* 2021 Mar 1;84(3):255-260. PMID: 33433134. **(2020, IF: 2.743, Medicine, General & Internal: 62/167=37.13%)**
81. Gantumur G, Batsaikhan B, Huang CI, Yeh ML, Huang CF, Lin YH, Lin TC, Liang PC, Liu TW, Lee JJ, Lin YC, Lin IL, Huang JF, Chuang WL, **Yu ML**, Tu HP, Dai CY\*. 2021. The association between hepatitis C virus infection and renal function. *J Chin Med Assoc.* 2021 Aug 1;84(8):757-765. PMID: 34074934. **(2020, IF: 2.743, Medicine, General & Internal: 62/167=37.13%)**
82. Tsai PC, Huang CI, Yeh ML, Huang CF, Hsieh MH, Yang JF, Hsu PY, Liang PC, Lin YH, Jang TY, Hsieh MY, Dai CY, Lin ZY, Chen SC, Huang JF\*, **Yu ML**, Chuang WL, Chang WY. 2021. Significant amelioration of hepatitis C virus infection in a hyperendemic area: longitudinal evidence from the COMPACT Study in Taiwan. *BMJ Open.* 2021 Mar 15;11(3):e042861. PMID: 33722868; PMCID: PMC7959235. **(2020, IF: 2.692, Medicine, General & Internal: 64/167=38.32%)**

#### 2020 First Author or Corresponding Author

83. Yeh ML, Huang CF, Huang CI, Holmes JA, Hsieh MH, Tsai YS, Liang PC, Tsai PC, Hsieh MY, Lin ZY, Chen SC, Huang JF, Dai CY, Chuang WL, Chung RT, **Yu ML\***. 2020. Hepatitis B-related outcomes following direct-acting antiviral therapy in Taiwanese patients with chronic HBV/HCV co-infection. *J Hepatol.* 2020 Jul;73(1):62-71. **(2020, IF: 25.083, Gastroenterology & Hepatology: 2/92=2.17%)**
84. Yeh ML, **Yu ML\***. Reply to "DAA and HBV/HCV co-infection: Glimmer of light and a few shades of grey". *J Hepatol.* 2020 Aug;73(2):462. **(2020, IF: 25.083, Gastroenterology & Hepatology: 2/92=2.17%)**
85. Huang JF, Dai CY, **Yu ML\***, Chuang WL. 2020. Letter to the Editors: Regional Epidemics of Nonalcoholic Fatty Liver Disease: Timing of Westernization and Ethnicity Matter. *Hepatology.* 2020 Aug;72(2):781. **(2020, IF: 17.425, Gastroenterology & Hepatology: 6/92=6.52%)**
86. Huang CF, Lai HC, Chen CY, Tseng KC, Kuo HT, Hung CH, Wang JH, Chen JJ, Lee PL, Chien RN, Yang CC, Lo GH, Tai CM, Lin CW, Kao JH, Liu CJ, Liu CH, Yan SL, Bair MJ, Lin CY, Su WW, Chu CH, Chen CJ, Tung SY, Lo CC, Cheng PN, Chiu YC, Wang CC, Cheng JS, Tsai WL, Lin HC, Huang YH, Yeh ML, Huang JF, Dai CY, Chuang WL, Tsai PC, Peng CY\*, **Yu ML\***. 2020. Extrahepatic Malignancy Among Patients With Chronic Hepatitis C After Antiviral Therapy: A Real-World Nationwide Study on Taiwanese Chronic Hepatitis C Cohort

- (T-COACH). *Am J Gastroenterol.* 2020 Aug;115(8):1226-1235. (2020, IF: 10.864, **Gastroenterology & Hepatology: 9/92=9.78%**)
87. Huang CF, Chiu YW, **Yu ML\***. 2020. Patient-centered outreach treatment toward micro-elimination of hepatitis C virus infection in hemodialysis patients. *Kidney Int.* 2020 Feb;97(2):421. (2020, IF: 10.612, **Urology & Nephrology: 4/89=4.49%**)
  88. Huang CF, **Yu ML\***. 2020. Daclatasvir plus asunaprevir in the treatment of uremic patients with chronic hepatitis C genotype 1b infection. *Kidney Int.* 2020 Mar;97(3):615. (2020, IF: 10.612, **Urology & Nephrology: 4/89=4.49%**)
  89. Huang CF, **Yu ML\***. 2020. Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy. *Clin Mol Hepatol.* 2020 Jul;26(3):251-260. (2020, IF: 6.074, **Gastroenterology & Hepatology: 23/92=25%**)
  90. Tsai YS, Yeh ML, Tsai PC, Huang CI, Huang CF, Hsieh MH, Liu TW, Lin YH, Liang PC, Lin ZY, Chen SC, Huang JF, Chuang WL, Dai CY\*, **Yu ML\***. 2020. Clusters of Circulating let-7 Family Tumor Suppressors Are Associated with Clinical Characteristics of Chronic Hepatitis C. *Int J Mol Sci.* 2020 Jul 13;21(14):4945. (2020, IF: 5.924, **Biochemistry & Molecular Biology: 67/295=22.71%**)
  91. Hsu WF, Chen CY, Tseng KC, Lai HC, Kuo HT, Hung CH, Tung SY, Wang JH, Chen JJ, Lee PL, Chien RN, Lin CY, Yang CC, Lo GH, Tai CM, Lin CW, Kao JH, Liu CJ, Liu CH, Yan SL, Bair MJ, Su WW, Chu CH, Chen CJ, Lo CC, Cheng PN, Chiu YC, Wang CC, Cheng JS, Tsai WL, Lin HC, Huang YH, Tsai PC, Huang JF, Dai CY, Chuang WL, **Yu ML\***, Peng CY\*. 2020. Sustained virological response to hepatitis C therapy does not decrease the incidence of systemic lupus erythematosus or rheumatoid arthritis. *Sci Rep.* 2020 Mar 25;10(1):5372. (2020, IF: 4.38, **Multidisciplinary sciences: 17/72=23.61%**)
  92. Jang TY, Huang CI, Yeh ML, Liang PC, Tsai PC, Lin YH, Hsieh MY, Hou NJ, Lin ZY, Chen SC, Huang JF, Dai CY, Huang CF\*, Chuang WL, **Yu ML\***. 2020. Improvement of hyperuricemia in chronic hepatitis C patients receiving directly acting antiviral agents. *J Gastroenterol Hepatol.* 2020 Mar;35(3):473-481. (2020, IF: 4.029, **Gastroenterology & Hepatology: 45/92=48.91%**)
  93. Huang CF, Yeh ML, Huang CI, Liang PC, Lin YH, Hsieh MY, Chen KY, Ko YM, Lin ZY, Chen SC, Huang JF, Dai CY, Chuang WL, **Yu ML\***. 2020. Ribavirin facilitates early viral kinetics in chronic hepatitis C patients receiving daclatasvir/asunaprevir. *J Gastroenterol Hepatol.* 2020 Jan;35(1):151-156. (2020, IF: 4.029, **Gastroenterology & Hepatology: 45/92=48.91%**)
  94. Tsai PC, Chen CY, Kuo HT, Hung CH, Tseng KC, Lai HC, Peng CY, Wang JH, Chen JJ, Lee PL, Chien RN, Yang CC, Lo GH, Kao JH, Liu CJ, Liu CH, Yan SL, Bair MJ, Lin CY, Su WW, Chu CH, Chen CJ, Tung SY, Tai CM, Lin CW, Lo CC, Cheng PN, Chiu YC, Wang CC, Cheng JS, Tsai WL, Lin HC, Huang YH, Yeh ML, Huang CF, Hsieh MH, Huang JF, Dai CY, Chung WL, Ke CK\*, **Yu ML\***. 2020. Successful Antiviral Therapy Reduces Risk of Schizophrenia Among Chronic Hepatitis C Patients: A Nationwide Real-World Taiwanese Cohort (T-COACH). *Open Forum Infect Dis.* 2020 Aug 31;7(10):ofaa397. (2020, IF: 3.835, **Infectious Diseases: 37/93= 39.78%**)
  95. Liang PC, Chen KY, Huang CH, Chang K, Lu PL, Yeh ML, Huang CF, Huang CI, Hsieh MH, Dai CY, Lin ZY, Chen SC, Chuang WL, Chen YH, Huang JF, **Yu ML\***. 2020. Viral Interference Between Dengue Virus and Hepatitis C Virus Infections. *Open Forum Infect Dis.* 2020 Jul 3;7(8):ofaa272. (2020, IF: 3.835, **Infectious Diseases: 37/93= 39.78%**)
  96. Dai CY, Huang JF, Chuang WL, **Yu ML\***. 2020. Severe acute exacerbation of HCV infection in cancer patients who undergo chemotherapy: some issues. *J Viral Hepat.* 2020 Dec;27(12):1508. (2020, IF: 3.728, **Infectious diseases: 41/93=44.09%**)
  97. **Yu ML\***, Chen PJ, Dai CY, Hu TH, Huang CF, Huang YH, Hung CH, Lin CY, Liu CH, Liu CJ, Peng CY, Ling HC, Kao JH, Chuang WL. 2020 Taiwan. Consensus Statement on the Management of Hepatitis C: Part (I) General Population. *J Formos Med Assoc.* 2020 Jun;119(6):1019-1040. Epub 2020 Apr 29. PMID: 32359879. (2020, IF: 3.282, **Medicine, General & Internal: 53/167=31.74%**)
  98. **Yu ML\***, Chen PJ, Dai CY, Hu TH, Huang CF, Huang YH, Hung CH, Lin CY, Liu CH, Liu CJ, Peng CY, Ling HC, Kao JH, Chuang WL. 2020 Taiwan. Consensus Statement on the Management of Hepatitis C: Part (II) Special Populations. *J Formos Med Assoc.* 2020 Jul;119(7):1135-1157. Epub 2020 Apr 27. PMID: 32354689. (2020, IF: 3.282, **Medicine, General & Internal: 53/167=31.74%**)
  99. Hsieh MH, Wu KT, Chen YY, Yang JF, Lin WY, Chang NC, Lin CY, Huang CK, Wang CL, Chuang HY, Lin SC, Hsu YK, Tsai YS, Chuang WL, **Yu ML\***, Dai CY\*. 2020. Higher NAFLD fibrosis score is associated with impaired eGFR. *J Formos Med Assoc.* 2020

Jan;119(1):496-503. (2020, IF: 3.282, Medicine, General & Internal: 53/167=31.74%)

100. Liu TW, Huang CF, Yeh ML, Tsai PC, Jang TY, Huang JF, Dai CY, Chuang WL, **Yu ML\***. 2020. Less liver fibrosis marker increment in overweight chronic hepatitis B patients observed by age-adjusted Fibrosis-4 Index. *BMJ Open Gastroenterol*. 2020 Dec;7(1):e000543.

## 2020 Co-author

101. Wong GL, Wong VW, Thompson A, Jia J, Hou J, Lesmana CRA, Susilo A, Tanaka Y, Chan WK, Gane E, Ong-Go AK, Lim SG, Ahn SH, **Yu ML**, Piratvisuth T, Chan HL\*: Asia-Pacific Working Group for Liver Derangement during the COVID-19 Pandemic. 2020. Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement. *Lancet Gastroenterol Hepatol*. 2020;Jun 22;5(8):776–87. (2020, IF: 18.486, **Gastroenterology & Hepatology: 5/92=5.43%**)
102. Dang H, Yeo YH, Yasuda S, Huang CF, Iio E, Landis C, Jun DW, Enomoto M, Ogawa E, Tsai PC, Le A, Liu M, Maeda M, Nguyen B, Ramrakhiani N, Henry L, Cheung R, Tamori A, Kumada T, Tanaka Y, **Yu ML**, Toyoda H, Nguyen MH\*. 2020. Cure with Interferon Free DAA is Associated with Increased Survival in Patients with HCV related HCC from both East and West. *Hepatology*. 2020 Jun;71(6):1910-1922. (2020, IF: 17.425, **Gastroenterology & Hepatology: 6/92=6.52%**)
103. Tseng TC, Peng CY, Hsu YC, Su TH, Wang CC, Liu CJ, Yang HC, Yang WT, Lin CH, **Yu ML**, Lai HC, Tanaka Y, Nguyen MH, Liu CH, Chen PJ, Chen DS, Kao JH\*. 2020. Baseline Mac-2 Binding Protein Glycosylation Isomer Level Stratifies Risks of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Oral Antiviral Therapy. *Liver Cancer*. 2020 Apr;9(2):207-220. (2020, IF: 11.74, **Gastroenterology & Hepatology: 7/92=7.61%**)
104. Hsu YC, Wong GL, Chen CH, Peng CY, Yeh ML, Cheung KS, Toyoda H, Huang CF, Trinh H, Xie Q, Enomoto M, Liu L, Yasuda S, Tanaka Y, Kozuka R, Tsai PC, Huang YT, Wong C, Huang R, Jang TY, Hoang J, Yang HI, Li J, Lee DH, Takahashi H, Zhang JQ, Ogawa E, Zhao C, Liu C, Furusyo N, Eguchi Y, Wong C, Wu C, Kumada T, Yuen MF, **Yu ML**, Nguyen MH\*. 2020. Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis B. *Am J Gastroenterol*. 2020 Feb;115(2):271-280. (2020, IF: 10.864, **Gastroenterology & Hepatology: 9/92=9.78%**)
105. Ogawa E, Toyoda H, Iio E, Jun DW, Huang CF, Enomoto M, Hsu YC, Haga H, Iwane S, Wong G, Lee DH, Tada T, Liu CH, Chuang WL, Hayashi J, Cheung R, Yasuda S, Tseng CH, Takahashi H, Tran S, Yeo YH, Henry L, Barnett SD, Nomura H, Nakamuta M, Dai CY, Huang JF, Yang HI, Lee MH, Jung Jun M, Kao JH, Eguchi Y, Ueno Y, Tamori A, Furusyo N, **Yu ML**, Tanaka Y, Nguyen MH\*; REAL-C Investigators, Ahn SB, Azuma K, Dohmen K, Yoon Jeong J, Jung JH, Kajiwara E, Kato M, Kawano A, Koyanagi T, Ooho A, Park SH, Satoh T, Shimoda S, Song DS, Takahashi K, Yeh ML, Yoon EL. 2020. HCV Cure Rates are Reduced in Patients with Active but not Inactive Hepatocellular Carcinoma- A Practice Implication. *Clin Infect Dis*. 2020 Dec 31;71(11):2840-2848. (2020, IF: 9.079, **Infectious Diseases: 3/93= 3.23%**)
106. Dai CY, **Yu ML**, Jong YJ\*, Ho CK\*. 2020. Familial clusters of the 2019 novel coronavirus diseases in Taiwan. *Travel Med Infect Dis*. 2020 Jul-Aug;36:101813. (2020, IF: 6.211, **Infectious Diseases: 9/93=9.68%**)
107. Yap DYH, Liu KSH, Hsu YC, Wong GLH, Tsai MC, Chen CH, Hsu CS, Hui YT, Li MKK, Liu CH, Kan YM, **Yu ML**, Yuen MF\*. 2020. Use of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairment. *Clin Mol Hepatol*. 2020 Oct;26(4):554-561. (2020, IF: 6.074, **Gastroenterology & Hepatology: 23/92=25%**)
108. Tanaka Y, Ogawa E, Huang CF, Toyoda H, Jun DW, Tseng CH, Hsu YC, Enomoto M, Takahashi H, Furusyo N, Yeh ML, Iio E, Yasuda S, Lam CP, Lee DH, Haga H, Yoon EL, Ahn SB, Wong G, Nakamuta M, Nomura H, Tsai PC, Jung JH, Song DS, Dang H, Maeda M, Henry L, Cheung R, Yuen MF, Ueno Y, Eguchi Y, Tamori A, **Yu ML**, Havashi J, Nguyen MH\*: REAL-C Investigators. 2020. HCC risk post-SVR with DAAs in East Asians: findings from the REAL-C cohort. *Hepatol Int*. 2020 Dec;14(6):1023-1033. (2020, IF: 6.047, **Gastroenterology & Hepatology: 24/92=26.09%**)
109. Huang YW, Hsu CW, Lu SN, **Yu ML**, Su CW, Su WW, Chien RN, Hsu CS, Hsu SJ, Lai HC, Oin A, Tseng KC, Chen PJ\*. 2020. Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B. *Hepatol Int*. 2020 Dec;14(6):997-1008. (2020, IF: 6.047, **Gastroenterology & Hepatology: 24/92=26.09%**)
110. Shabangu CS, Huang JF, Hsiao HH, **Yu ML**, Chuang WL, Wang SC\*. 2020. Liquid Biopsy for the Diagnosis of Viral Hepatitis, Fatty Liver Steatosis, and Alcoholic Liver Diseases. *Int J Mol Sci*. 2020 May 25;21(10):E3732. (2020, IF: 5.924, **Biochemistry & Molecular Biology:**

67/295=22.71%)

111. Yang HI, Yeh ML, Wong GL, Peng CY, Chen CH, Trinh HN, Cheung KS, Xie Q, Su TH, Kozuka R, Lee DH, Ogawa E, Zhao C, Ning HB, Huang R, Li J, Zhang JQ, Ide T, Xing H, Iwane S, Takahashi H, Wong C, Wong C, Lin CH, Hoang J, le A, Henry L, Toyoda H, Ueno Y, Gane EJ, Eguchi Y, Kurosaki M, Wu C, Liu C, Shang J, Furusyo N, Enomoto M, Kao JH, Yuen MF, **Yu ML**, Nguyen MH\*. **2020**. REAL-B (Real-world Effectiveness from the Asia Pacific Rim Liver Consortium for HBV) Risk Score for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated with Oral Antiviral Therapy. *J Infect Dis.* 2020 Jan 14;221(3):389-399. (2020, IF: 5.226, Infectious Diseases: 18/93= 19.35%)
112. Chen VL, Yeh ML, Yang JD, Leong J, Huang DQ, Toyoda H, Chen YL, Guy J, Maeda M, Tsai PC, Huang CF, Yasuda S, Le AK, Dang H, Giama NH, Ali HA, Zhang N, Wang X, Jun DW, Tseng CH, Hsu YC, Huang JF, Dai CY, Chuang WL, Zhu O, Dan YY, Schwartz M, Roberts LR, **Yu ML**, Nguven MH\*. **2020**. Effects of Cirrhosis and Diagnosis Scenario in Metabolic-Associated Fatty Liver Disease-Related Hepatocellular Carcinoma. *Hepatol Commun.* 2020 Sep 24;5(1):122-132. PMID: PMC7789832. (2020, IF: 5.073, Gastroenterology & Hepatology: 32/92=34.78%)
113. Yeo YH, Tseng TC, Hosaka T, Cunningham C, Fung JYY, Ho HJ, Kwak MS, Trinh HN, Ungtrakul T, **Yu ML**, Kobavashi M, Le AK, Henry L, Li J, Zhang J, Sriprayoon T, Jeong D, Tanwandee T, Gane E, Cheung RC, Wu CY, Lok AS, Lee HS, Suzuki F, Yuen MF, Kao JH, Yang HI, Nguyen MH\*. **2020**. Incidence, Factors, and Patient-Level Data for Spontaneous HBsAg Seroclearance: A Cohort Study of 11,264 Patients. *Clin Transl Gastroenterol.* 2020 Sep;11(9):e00196. (2020, IF: 4.488, Gastrienterology & Hepatology : 37/92=40.22%)
114. Li PK, Bavanandan S, Mohamed R, Szeto CC, Wong VW, Chow KM, Dan YY, Huang CC, Lai CL, Tanwandee T, Teo BW, Wong GL, Yeoh EK, Iseki K, Leung CB, Park HC, Kanjanabuch T, Lu W, Fung J, Jia J, Kanda E, Law MC, Liu H, Loo CK, Mak SK, Lui SL, Tang HL, Wang AY, **Yu ML**, Cheung M, Jadoul M\*. **2020**. 2018 Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C in Chronic Kidney Disease Guideline Implementation: Asia Summit Conference Report. *Kidney Int Rep.* 2020 May 21;5(8):1129-1138. (2020, IF: 4.164, Urology & Nephrology: 22/89=24.72%)
115. Jang TY, Wei YJ, Hsu CT, Hsu PY, Liu TW, Lin YH, Liang PC, Hsieh MH, Ko YM, Tsai YS, Chen KY, Lin CC, Tsai PC, Wang SC, Huang CI, Yeh ML, Lin ZY, Chen SC, Chuang WL, Huang JF, Dai CY, Huang CF\*. **Yu ML**. **2020**. Serial serologic changes of hepatitis D virus in chronic hepatitis B patients receiving nucleos(t)ides analogues therapy. *J Gastroenterol Hepatol.* 2020 Nov;35(11):1886-1892. (2020, IF: 4.029, Gastroenterology & Hepatology: 45/92=48.91%)
116. Yeh ML, Huang JF, **Yu ML**, Chuang WL\*. **2020**. Hepatitis b infection: progress in identifying patients most likely to respond to peginterferon alfa. *Expert Rev Gastroenterol Hepatol.* 2020 Dec 24:1-9. (2020, IF: 3.869, Gastroenterology & Hepatology: 47/92=51.09%)
117. Lin CY, Wang WH, Urbina AN, Tseng SP, Lu PL, Chen YH, **Yu ML**, Wang SF\*. **2020**. Importation of SARS-CoV-2 infection leads to major COVID-19 epidemic in Taiwan. *Int J Infect Dis.* 2020 Jun 13;97:240-244. (2020, IF: 3.623, Infectious Diseases: 45/93= 48.39%)
118. Gau YC, Hsiao HH\*, Huang JF, **Yu ML**. **2020**. Letter to the editors: Successful eradication of HCV by short-course DAAs in HCV-Positive donor to HCV-Negative recipient during Haplo-HSCT. *J Formos Med Assoc.* 2020 Nov;119(11):1717-1718. (2020, IF: 3.282, Medicine, General & Internal: 53/167=31.74%)
119. Lee JJ, Wei YJ, Lin MY, Niu SW, Hsu PY, Huang JC, Jang TY, Yeh ML, Huang CI, Liang PC, Lin YH, Hsieh MY, Hsieh MH, Chen SC, Dai CY, Lin ZY, Chen SC, Huang JF, Chang JM, Hwang SJ, Huang CF, Chiu YW\*, Chuang WL\*. **Yu ML**. **2020**. The applicability of non-invasive methods for assessing liver fibrosis in hemodialysis patients with chronic hepatitis C. *PLoS One.* 2020 Nov 20;15(11):e0242601. (2020, IF: 3.24, Multidisciplinary sciences: 26/72=36.11%)
120. Hsu PY, Hsu CT, Yeh ML, Huang CF, Huang CI, Liang PC, Lin YH1, Hsieh MY, Wei YJ, Hsieh MH, Dai CY, Lin ZY, Chen SC, Huang JF\*, **Yu ML**, Chuang WL. **2020**. Early Fibrosis but Late Tumor Stage and Worse Outcomes in Hepatocellular Carcinoma Patients Without Hepatitis B or Hepatitis C. *Digest Dis Sci.* 2020 Jul;65(7):2120-2129. (2020, IF: 3.199, Gastroenterology & Hepatology: 64/92=69.57%)
121. Lin ZY\*, Wang JH, Yeh ML, Huang CI, Kee KM, Yen YH, Chen SC, Huang CF, Huang JF, Dai CY, **Yu ML**, Chuang WL. **2020**. Primary culture of aspiration residual specimens improves the diagnostic accuracy between hepatocellular carcinoma and benign nodules. *Kaohsiung J Med Sci.* 2020 Jun;36(6):460-466. (2020, IF: 2.744, Medicine, Research & Experimental: 93/140=66.43%)

122. Lin ZY\*, Wang JH\*, Yeh ML, Huang CI, Kee KM, Yen YH, Chen SC, Huang CF, Huang JF, Dai CY, **Yu ML**, Chuang WL. **2020**. Primary cultures of aspiration residual specimens predict outcomes of hepatocellular carcinoma patients receiving curative treatment. *Kaohsiung J Med Sci*. 2020 Sep;36(9):750-756. (2020, IF: 2.744, **Medicine, Research & Experimental: 93/140=66.43%**)
123. Huang CF\*, Dai CY, Yeh ML, Huang CI, Lee HC, Lai WT, Liang PC, Lin YH, Hsieh MY, Hou NJ, Lin ZY, Chen SC, Huang JF, Chuang WL, **Yu ML**. **2020**. Cure or curd: Modification of lipid profiles and cardio-cerebrovascular events after hepatitis C virus eradication. *Kaohsiung J Med Sci*. 2020 Nov;36(11):920-928. (2020, IF: 2.744, **Medicine, Research & Experimental: 93/140=66.43%**)
124. Wang CW, Chuang HY, Chiang HC, Huang PC, **Yu ML**, Dai CY\*. **2020**. Risk of Hepatitis C Virus Infection in Injecting and Non-Injecting Drug Users Receiving Opioid Substitution Therapy. *J Chin Med Assoc*. 2020 May;83(5):454-460. (2020, IF: 2.743, **Medicine, General & Internal: 62/167=37.13%**)

### 2019 First Author or Corresponding Author

125. Huang CF, **Yu ML\***. **2019**. Direct-acting antivirals response in hepatocellular carcinoma: Does the presence of hepatocellular carcinoma matter? *Clin Mol Hepatol*. 2019 Feb 11;25(2):168-171. (2020, IF: 6.074, **Gastroenterology & Hepatology: 23/92=25%**)
126. Perez S, Kaspi A, Domovitz T, Davidovich A, Lavi-Itzkovitz A, Meirson T, Alison Holmes J, Dai CY, Huang CF, Chung RT, Nimer , El-Osta A, Yaari G, Stemmer SM, **Yu ML\***, Haviv I\*, Gal-Tanamy M\*. **2019**. Hepatitis C virus leaves an epigenetic signature post cure of infection by direct-acting antivirals. *PLoS Genet*. 2019 Jun 19;15(6):e1008181. (2020, IF: 5.917, **Genetics & Heredity: 27/175= 15.42%**)
127. Huang CF, Hung CH, Cheng PN, Bair MJ, Huang YH, Kao JH, Hsu SJ, Lee PL, Chen JJ, Chien RN, Peng CY, Lin CY, Hsieh TY, Cheng CH, Dai CY, Huang JF, Chuang WL, **Yu ML\***. **2019**. An open-label, randomized, active control trial of 8 versus 12 weeks of elbasvir/grazoprevir for naive chronic hepatitis C genotype 1b patients with mild fibrosis (EGALITE): Impact of baseline viral loads and NS5A resistance-associated substitution. *J Infect Dis*. 2019 Jul 19;220(4):557-566 (2020, IF: 5.226, **Infectious Diseases: 18/93= 19.35%**)
128. Wang CW, Dai CY, Chuang TM, Huang CF, Yeh ML, Huang CI, Lin ZY, Chen SC, Huang JF, **Yu ML\***, Chuang WL. **2019**. Fulminant Emphysematous Pancreatic Pseudocyst: Infected with Normal Skin Flora. *Am J Med*. 2019 Feb;132(2):e41-e2. (2020, IF: 4.965, **Medicine General & Internal: 30/167= 17.96%**)
129. Huang CF, Wang SC, Yeh ML, Huang CI, Tsai PC, Lin ZY, Chen SC, Dai CY, Huang JF, Chuang WL, Chen A, **Yu ML\***. **2019**. Association of serial serum major histocompatibility complex class I chain-related A measurements with hepatocellular carcinoma in chronic hepatitis C patients after viral eradication. *J Gastroenterol Hepatol*. 2019 Jan; 34(1) :249-55. (2020, IF: 4.029, **Gastroenterology & Hepatology: 45/92=48.91%**)
130. Huang JF, Tsai PC, Yeh ML, Huang CF, Huang CI, Hsieh MH, Dai CY, Yang JF, Chen SC, **Yu ML\***, Chuang WL, Chang WY. **2019**. Risk stratification of non-alcoholic fatty liver disease across body mass index in a community basis. *J Formos Med Assoc*. 2020 Jan;119(1 Pt 1):89-96. Epub 2019 Apr 2. PMID: 30952479. (2020, IF: 3.282, **Medicine, General & Internal: 53/167=31.74%**)
131. **Yu ML**, Hung CH, Huang YH, Peng CY, Lin CY, Cheng PN, Chien RN, Hsu SJ, Liu CH, Huang CF, Su CW, Huang JF, Liu CJ, Kao JH, Chuang WL\*, Chen PJ, Chen DS. **2019**. Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions. *J Formos Med Assoc*. 2019 Feb;118(2):556-64. (2020, IF: 3.282, **Medicine, General & Internal: 53/167=31.74%**)
132. Huang CF, Yeh ML, Huang CI, Liang PC, Lin YH, Hsieh MY, Wei YJ, Lin ZY, Chen SC, Huang JF, Dai CY, Chuang WL, **Yu ML\***. **2019**. Equal treatment efficacy of direct-acting antivirals in patients with chronic hepatitis C and hepatocellular carcinoma? A prospective cohort study. *BMJ Open*. 2019 May 5;9(5):e026703. (2020, IF: 2.692, **Medicine, General & Internal: 64/167=38.32%**)

### 2019 Co-author

133. Liu X, Duan X, Holmes JA, Li W, Lee SH, Tu Z, Zhu C, Salloum S, Lidofskv A, Schaefer EA, Cai D, Li S, Wang H, Huang Y, Zhao Y, **Yu ML**, Xu Z, Chen L, Hong J, Lin W, Chung RT\*. **2019**. A Long Noncoding RNA Regulates Hepatitis C Virus Infection Through Interferon Alpha-Inducible Protein 6. *Hepatology*. 2019 Mar;69(3):1004-19. (2020, IF: 17.425, **Gastroenterology & Hepatology: 6/92=6.52%**)

134. Wang CW, Chuang HY, Liao KW, **Yu ML**, Dai CY, Chang WT, Tsai CH, Chiang HC, Huang PC\*. **2019**. Urinary thiodiglycolic acid is associated with increased risk of non-alcoholic fatty liver disease in children living near a petrochemical complex. *Environ Int.* 2019 Jul 17;131:104978. (2020, IF: 9.621, *Environmental Sciences*: 14/274=5.11%)
135. Younossi ZM, Henry L, J PO, Tanaka A, Eguchi Y, Mizokami M, Lim YS, Dan YY, **Yu ML**, Stepanova M. **2019**. Systematic review with meta-analysis: extrahepatic manifestations in chronic hepatitis C virus-infected patients in East Asia. *Aliment Pharmacol Ther.* 2019 Mar;49(6):644-53. (2020, IF: 8.171, *Pharmacology & Pharmacy*: 13/276= 4.71%)
136. Wang CW, Liao KW, Chan CC, **Yu ML**, Chuang HY, Chiang HC, Huang PC. **2019**. Association between urinary thiodiglycolic acid level and hepatic function or fibrosis index in school-aged children living near a petrochemical complex. *Environ Pollut.* 2019 Jan;244:648-56. (2020, IF: 8.071, *Environmental Sciences*: 23/274=8.39%)
137. Kanda T, Lau GKK, Wei L, Moriyama M, **Yu ML**, Chuang WL, Ibrahim A, Lesmana CRA, Sollano J, Kumar M, Jindal A, Sharma BC, Hamid SS, Dokmeci AK, Mamun Al M, McCaughan GW, Wasim J, Crawford DHG, Kao JH, Yokosuka O, Sarin SK, Omata M\*. **2019**. APASL clinical practice recommendation: how to treat HCV-infected patients with renal impairment? *Hepatology Int.* 2019 Mar;13(2):103-9. (2020, IF: 6.047, *Gastroenterology & Hepatology*: 24/92=26.09%)
138. Kanda T, Lau GKK, Wei L, Moriyama M, **Yu ML**, Chuang WL, Ibrahim A, Lesmana CRA, Sollano J, Kumar M, Jindal A, Sharma BC, Hamid SS, Kadir Dokmeci A, Mamun-Al-Mahtab, McCaughan GW, Wasim J, Crawford DHG, Kao JH, Ooka Y, Yokosuka O, Sarin SK, Omata M\*. **2019**. APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation. *Hepatology Int.* 2019 Nov;13(6):649-661. (2020, IF: 6.047, *Gastroenterology & Hepatology*: 24/92=26.09%)
139. Huang CF, Iio E, Jun DW, Ogawa E, Toyoda H, Hsu YC, Haga H, Iwane S, Enomoto M, Lee DH, Wong G, Liu CH, Tada T, Chuang WL, Cheung R, Hayashi J, Tseng CH, Yasuda S, Tran S, Kam L, Henry L, Jeong JY, Nomura H, Park SH, Nakamuta M, Huang JF, Tai CM, Lo GH, Lee MH, Yang HI, Kao JH, Tamori A, Eguchi Y, Ueno Y, Furusyo N, Tanaka Y, **Yu ML**, Nguyen MH\*; REAL-C Investigators. **2019**. Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium. *Hepatology Int.* 2019 Sep;13(5):587-598. (2020, IF: 6.047, *Gastroenterology & Hepatology*: 24/92=26.09%)
140. Yeh ML, Huang CI, Huang CF, Hsieh MH, Liu TW, Lin YH, Liang PC, Hsieh MY, Lin ZY, Chen SC, Huang JF, Kuo PL, Dai CY\*, **Yu ML**, Chuang WL. **2019**. Pretreatment Hepatitis B Viral Load Predicts Long-Term Hepatitis B Response After Anti-Hepatitis C Therapy in Hepatitis B/C Dual-Infected Patients. *J Infect Dis.* 2019 Apr 8;219(8):1224-1233. (2020, IF: 5.226, *Infectious Diseases*: 18/93= 19.35%)
141. Jun T, Hsu YC, Ogawa S, Huang YT, Yeh ML, Tseng CH, Huang CF, Tai CM, Dai CY, Huang JF, Chuang WL, **Yu ML**, Tanaka Y\*, Nguyen MH\*. **2019**. Mac-2 Binding Protein Glycosylation Isomer as a Hepatocellular Carcinoma Marker in Patients With Chronic Hepatitis B or C Infection. *Hepatology Commun.* 2019 Apr;3(4):493-503. (2020, IF: 5.073, *Gastroenterology & Hepatology*: 32/92=34.78%)
142. Yeh ML, Huang JF, Dai CY, **Yu ML**, Chuang WL\*. **2019**. Pharmacokinetics and pharmacodynamics of pegylated interferon for the treatment of hepatitis B. *Expert Opin Drug Metab Toxicol.* 2019 Oct;15(10):779-785. (2020, IF: 4.481, *Toxicology*: 22/93= 23.66%)
143. Lin CW\*, Hsu CC, Hsieh PM, Chen YS, Lo GH, Lin HY, Dai CY, Huang JF, Chuang WL, Chen YL, **Yu ML**. **2019**. Axl and autophagy LC3 expression in tumors is strongly associated with clinical prognosis of hepatocellular carcinoma patients after curative resection. *Cancer Med.* 2019 Jul; 8(7):3453-3463. (2020, IF: 4.452, *Oncology*: 108/242=44.63%)
144. Yeh ML, Huang CF, Huang CI, Dai CY, Lin IH, Liang PC, Hsieh MH, Lin ZY, Chen SC, Huang JF\*, Chen JJ\*, **Yu ML**, Chuang WL. **2019**. Wisteria floribunda agglutinin-positive Mac-2-binding protein in the prediction of disease severity in chronic hepatitis B patients. *PLoS One.* 2019 Aug 8;14(8):e0220663. (2020, IF: 3.24, *Multidisciplinary sciences*: 26/72=36.11%)
145. Batsaikhan B, Lu MY, Yeh ML, Huang CI, Huang CF, Lin ZY, Chen SC, Huang JF, Hsieh PH, Chuang WL, Lee JC, **Yu ML**, Dai CY\*. **2019**. Elevated interleukin-4 levels predicted advanced fibrosis in chronic hepatitis C. *J Chin Med Assoc.* 2019 Apr;82(4):277-81. (2020, IF: 3.282, *Medicine, General & Internal*: 53/167=31.74%)
146. Batsaikhan B, Gantumur G, Huang CI, Yeh ML, Huang CF, Lin ZY, Chen SC, Huang JF, **Yu ML**, Chuang WL, Lee JC, Dai CY\*. **2019**. Elevated serum ferritin level associated with hepatic steatosis and fibrosis in hepatitis C virus-infected patients. *J Chin Med Assoc.* 2019 Feb;82(2):99-104. (2020, IF: 3.282, *Medicine, General & Internal*: 53/167=31.74%)

147. Tai CM, Yen YC, Bair MJ, Tseng CH, Chang TT, Huang CF, Yeh ML, Dai CY, Chuang WL, **Yu ML**, Huang JF\*. **2019**. Integrated care for methadone maintenance patients with hepatitis C virus infection. *Kaohsiung J Med Sci*. 2019 Aug;35(8):501-507. (2020, IF: 2.744, **Medicine, Research & Experimental: 93/140=66.43%**)
148. Yeh ML, Huang CF, Huang CI, Hsieh MY, Hou NJ, Lin IH, Liang PC, Tsai YS, Hsieh MH, Lin ZY, Chen SC, Dai CY, Huang JF\*, **Yu ML**, Chuang WL. **2019**. The prognostic factors between different viral etiologies among advanced hepatocellular carcinoma patients receiving sorafenib treatment. *Kaohsiung J Med Sci*. 2019 Oct;35(10):624-632. (2020, IF: 2.744, **Medicine, Research & Experimental: 93/140=66.43%**)
149. Lin TY, Yeh ML, Huang CF, Huang CI, Dai CY, Hsieh MH, Chen SC, Huang JF\*, **Yu ML**, Chuang WL. **2019**. Disease progression of nonalcoholic steatohepatitis in Taiwanese patients: a longitudinal study of paired liver biopsies. *Eur J Gastroenterol Hepatol*. 2019 Feb;31(2):224-9. (2020, IF: 2.568, **Gastroenterology & Hepatology: 75/92=81.52%**)
150. Hsi E, Wang YS, Huang CW, **Yu ML**, Juo SH\*, Liang CL\*. **2019**. Genome-wide DNA hypermethylation and homocysteine increase a risk for myopia. *Int J Ophthalmol*. 2019 12(1):38-45. (2020, IF: 2.031, **Ophthalmology: 41/62= 66.13%**)
151. Liu CH, **Yu ML**, Peng CY, Hsieh TY, Huang YH, Su WW, Cheng PN, Lin CL, Lo CC, Chen CY, Chen JJ, Ma O, Brooks-Rooney C, Kao JH\*. **2019**. Real-world anti-viral treatment decisions among chronic hepatitis C patients in Taiwan: The INITIATE study. *J Formos Med Assoc*. 2019 Jun;118(6):1014-1023. Epub 2018 Nov 15. PMID: 30448077. (2020, IF: 3.282, **Medicine, General & Internal: 53/167=31.74%**)

#### 2018 First Author or Corresponding Author

152. Chen VL, Yeh ML, Le AK, Jun M, Saeed WK, Yang JD, Huang CF, Lee HY, Tsai PC, Lee MH, Giama N, Kim NG, Nguven PP, Dang H, Ali HA, Zhang N, Huang JF, Dai CY, Chuang WL, Roberts LR, Jun DW, Lim YS, **Yu ML\***, Nguyen MH\*. **2018**. Anti-viral therapy is associated with improved survival but is underutilised in patients with hepatitis B virus-related hepatocellular carcinoma: real-world east and west experience. *Aliment Pharmacol Ther*. 2018 Jul;48(1):44-54. (2020, IF: 8.171, **Pharmacology & Pharmacy: 13/276= 4.71%**)
153. Huang CF, Yeh ML, Huang CI, Liang PC, Lin YH, Lin ZY, Chen SC, Huang JF, Dai CY, Chuang WL, **Yu ML\***. Post-treatment fibrotic modifications overwhelm pretreatment liver fibrosis in predicting HCC in CHC patients with curative antivirals. *Hepatol Int*. **2018** Nov;12(6):544-551. (2020, IF: 6.047, **Gastroenterology & Hepatology: 24/92=26.09%**)
154. Lin CW, Chen YS, Lin CC, Lee PH, Lo GH, Hsu CC, Hsieh PM, Koh KW, Chou TC, Dai CY, Huang JF, Chuang WL, Chen YL, **Yu ML\***. **2018**. Autophagy-related gene LC3 expression in tumor and liver microenvironments significantly predicts recurrence of hepatocellular carcinoma after surgical resection. *Clin Transl Gastroenterol*. 2018 Jul 2;9(6):166. (2020, IF: 4.488, **Gastroenterology & Hepatology : 37/92=40.22%**)
155. Huang CF, Yeh ML, Huang CI, Lin ZY, Chen SC, Huang JF, Dai CY, Chuang WL, Chen JJ\*, **Yu ML\***. **2018**. Toll-like 1 genetic variants determine fibrosis regression in chronic hepatitis C patients with curative antivirals. *Sci Rep*. 2018 Oct 10;8(1):15058. (2020, IF: 4.38, **Multidisciplinary sciences: 17/72=23.61%**)
156. Huang CF, Wang SC, Chang WT, Yeh ML, Huang CI, Lin ZY, Chen SC, Chuang WL, Huang JF, Dai CY, Chen YL, **Yu ML\***. **2018**. Lower protein expression levels of MHC class I chain-related gene A in hepatocellular carcinoma are at high risk of recurrence after surgical resection. *Sci Rep*. 2018 Oct 25;8(1):15821. (2020, IF: 4.38, **Multidisciplinary sciences: 17/72=23.61%**)
157. Huang CF, Yeh ML, Huang CI, Lin ZY, Chen SC, Dai CY, Huang JF, Chuang WL, **Yu ML\***. **2018**. Interference of hepatitis B virus dual infection in platelet count recovery in chronic hepatitis C patients with curative antiviral therapy. *J Gastroenterol Hepatol*. 2018 May;33(5):1108-1114. (2020, IF: 4.029, **Gastroenterology & Hepatology: 45/92=48.91%**)
158. Tsai PC, Liu TW, Huang CF, Yeh ML, Dai CY, Chuang WL, Huang JF, **Yu ML\***. **2018**. A real world cost effectiveness analysis of interferon-based therapy for HCV naïve super-responders. *J Chin Med Assoc*. 2018 Aug;81(8):670-675. (2020, IF: 3.282, **Medicine, General & Internal: 53/167=31.74%**)
159. **Yu ML**. **2018**. Reply to "The choice of antiviral therapy for hepatitis C recurrence after liver transplantation in the real world". *J Formos Med Assoc*. 2018 Nov;117(11):1038-39. (2020, IF: 3.282, **Medicine, General & Internal: 53/167=31.74%**)



160. **Yu ML**, Chen YL, Huang CF, Lin KH, Yeh ML, Huang CI, Hsieh MH, Lin ZY, Chen SC, Huang JF, Dai CY, Chuang WL\*. **2018**. Paritaprevir/ritonavir/ombitasvir plus dasabuvir with ribavirin for treatment of recurrent chronic hepatitis C genotype 1 infection after liver transplantation: Real-world experience. *J Formos Med Assoc.* 2018 Jun;117(6):518-526. (2020, **IF: 3.282, Medicine, General & Internal: 53/167=31.74%**)
161. Hsieh MH, Yeh ML, Su TH, Liu TW, Huang CF, Huang CI, Wang SC, Huang JF, Dai CY, Kao JH, Chuang WL, Chen PJ, Liu CJ\*, **Yu ML\***. **2018**. Boceprevir-based triple therapy to rescue HCV genotype 1/HBV dually infected patients refractory to peginterferon plus ribavirin combination therapy in Taiwan. *J Formos Med Assoc.* 2018 Jun;117(6):497-504. (2020, **IF: 3.282, Medicine, General & Internal: 53/167=31.74%**)
162. Liu TW, Tsai PC, Huang CI, Tsai YS, Wang SC, Ko YM, Lin CC, Chen KY, Liang PC, Lin YH, Hsieh MY, Hou NJ, Huang CF, Yeh ML, Lin ZY, Chen SC, Dai CY, Chuang WL, Huang JF, **Yu ML\***. **2018**. Identification of treatment-experienced hepatitis C patients with poor cost-effectiveness of pegylated interferon plus ribavirin from a real-world cohort. *J Formos Med Assoc.* 2018 Jan;117(1):54-62. (2020, **IF: 3.282, Medicine, General & Internal: 53/167=31.74%**)
163. Liang PC, Lin PC, Huang CI, Huang CF, Yeh ML, Zeng YS, Hsu WY, Hsieh MY, Lin ZY, Chen SC, Huang JF, Dai CY, Chuang WL, Chiou SS\*, **Yu ML\***. **2018**. The treatment outcome and impact on blood transfusion demand of Peg-interferon/ribavirin in thalassemic patients with chronic hepatitis C. *J Formos Med Assoc.* 2018 Jan;117(1):14-23. (2020, **IF: 3.282, Medicine, General & Internal: 53/167=31.74%**)
164. Hsieh MH, **Yu ML\***. **2018**. Reply to "Rescue for interferon failures in HCV genotype 1/HBV dually infection". *J Formos Med Assoc.* 2018 Sep;117(9):861-862. (2020, **IF: 3.282, Medicine, General & Internal: 53/167=31.74%**)
165. Huang CI, Huang CF, Yeh ML, Lin YH, Liang PC, Liu SV, Hsieh MH, Lin ZY, Chen SC, Huang JF, Chuang WL, Dai CY\*, **Yu ML\***. **2018**. Role of IL-28B genetic variants in HCV-related liver disease severity in patients with different viral genotypes. *Medicine (Baltimore).* 2018 Mar;97(10):e9782. (2020, **IF: 1.889, Medicine, General & Internal: 99/167=59.28%**)
166. Dai CY, Tsai YS, Chou WW, Liu T, Huang CF, Wang SC, Tsai PC, Yeh ML, Hsieh MY, Huang CI, Vanson Liu SY, Huang JF, Chuang WL, **Yu ML\***. **2018**. The IL-6/STAT3 pathway upregulates microRNA-125b expression in hepatitis C virus infection. *Oncotarget.* 2018 Jan 10;9(13):11291-11302. (2016, **IF: 5.168, Oncology: 44/217=20.27%**)

### 2018 Co-author

167. Mücke MM, Backus LI, Mücke VT, Coppola N, Preda CM, Yeh ML, Tang LSY, Belperio PS, Wilson EM, **Yu ML**, Zeuzem S, Herrmann E, Vermehren J\*. **2018**. Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis. *Lancet Gastroenterol Hepatol.* 2018 Mar; 3(3): 172-180. (2020, **IF: 18.486, Gastroenterology & Hepatology: 5/92=5.43%**)
168. Liu CH, **Yu ML**, Peng CY, Hsieh TY, Huang YH, Su WW, Cheng PN, Lin CL, Lo CC, Chen CY, Chen JJ, Ma Q, Brooks-Rooney C, Kao JH\*. **2018**. Comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting antiviral agents in hepatitis C patients in Taiwan. *Aliment Pharmacol Ther.* 2018 Dec;48(11-12):1290-300. (2020, **IF: 8.171, Pharmacology & Pharmacv: 13/276= 4.71%**)
169. Hsu YC, Jun T, Huang YT, Yeh ML, Lee CL, Ogawa S, Cho SH, Lin JT, **Yu ML**, Nguven MH\*, Tanaka Y\*. **2018**. Serum M2BPGi level and risk of hepatocellular carcinoma after oral anti-viral therapy in patients with chronic hepatitis B. *Aliment Pharmacol Ther.* 2018 Nov;48(10):1128-1137. (2020, **IF: 8.171, Pharmacology & Pharmacv: 13/276= 4.71%**)
170. Zhao C, Jin M, Le RH, Le MH, Chen VL, Jin M, Wong GL, Wong VW, Lim YS, Chuang WL, **Yu ML**, Nguyen MH\*. **2018**. Poor adherence to hepatocellular carcinoma surveillance: A systematic review and meta-analysis of a complex issue. *Liver Int.* 2018 Mar;38(3):503-14. (2020, **IF: 5.828, Gastroenterology & Hepatology: 25/92=27.17%**)
171. Jun TW, Nguyen MH, **Yu ML**. **2018**. Author response to "Cryptogenic hepatocellular carcinoma (HCC) had worse overall survival of disease than viral HCC patients". *Liver Int.* 2018 Jun;38(6):1141. (2020, **IF: 5.828, Gastroenterology & Hepatology: 25/92=27.17%**)
172. Jun TW, Yeh ML, Yang JD, Chen VL, Nguven P, Giama NH, Huang CF, Hsing AW, Dai CY, Huang JF, Chuang WL, Roberts LR, **Yu ML**, Nguyen MH\*. **2018**. More advanced disease and worse survival in cryptogenic compared to viral hepatocellular carcinoma. *Liver Int.* 2018 May;38(5):895-902. (2020, **IF: 5.828, Gastroenterology & Hepatology: 25/92=27.17%**)

173. Huang JF, Huang CF, Yeh ML, Dai CY, **Yu ML**, Chuang WL. **2018**. Updates in the management and treatment of HCV genotype 3, what are the remaining challenges? *Expert Rev Anti Infect Ther.* 2018 Dec;16(12):907-912. (2020, IF: 5.091, Pharmacology & Pharmacy: 61/276=22.10%)
174. Kao JH, **Yu ML**, Chen CY, Peng CY, Chen MY, Tang H, Chen O, Wu JJ. **2018**. Twelve-week Ravidasvir plus ritonavir-boosted Danoprevir and ribavirin for non-cirrhotic HCV genotype 1 patients: A phase 2 study. *J Gastroenterol Hepatol.* 2018 Aug;33(8):1507-1510. (2020, IF: 4.029, Gastroenterology & Hepatology: 45/92=48.91%)
175. Batsaikhan B, Huang CI, Yeh ML, Huang CF, Liang PC, Hsieh MY, Huang JF, **Yu ML**, Chuang WL, Lee JC, Lee PL\*, Dai CY\*. **2018**. Association between crvoglobulinemia and liver fibrosis in chronic hepatitis C patients. *J Gastroenterol Hepatol.* 2018 Nov;33(11):1897-1903 (2020, IF: 4.029, Gastroenterology & Hepatology: 45/92=48.91%)
176. Jang TY, Yeh ML, Huang CI, Lin ZY, Chen SC, Hsieh MH, Dai CY, Huang JF, Huang CF, Chuang WL, **Yu ML**. **2018**. Association of hyperuricemia with disease severity in chronic hepatitis C patients. *PLoS One.* 2018 Nov 5;13(11):e0207043. (2020, IF: 3.24, Multidisciplinary sciences: 26/72=36.11%)
177. Lin CW, Chen YS, Lin CC, Lee PH, Lo GH, Hsu CC, Hsieh PM, Koh KW, Bair MJ, Dai CY, Huang JF, Chuang WL, Chen YL, **Yu ML**. **2018**. Significant predictors of overall survival in patients with hepatocellular carcinoma after surgical resection. *PLoS One.* 2018 13(9):e0202650. (2020, IF: 3.24, Multidisciplinary sciences: 26/72=36.11%)
178. Dai CY, Lin CY, Tsai PC, Lin PY, Yeh ML, Huang CF, Chang WT, Huang JF, **Yu ML**, Chen YL\*. **2018**. Impact of tumor size on the prognosis of hepatocellular carcinoma in patients who underwent liver resection. *J Chin Med Assoc.* 2018 Feb;81(2):155-163. (2020, IF: 2.743, Medicine, General & Internal: 62/167=37.13%)
179. Yeh ML, Huang CI, Huang CF, Hsieh MH, Hsieh MY, Lin ZY, Chen SC, Huang JF, Kuo PL, Kuo HT\*, Dai CY\*, **Yu ML**, Chuang WL. **2018**. Post-treatment alpha fetoprotein and platelets predict hepatocellular carcinoma development in dual-infected hepatitis B and C patients after eradication of hepatitis C. *Oncotarget.* 2018 Jan; 9(15): 12240-12249. (2016, IF: 5.168, Oncology: 44/217=20.27%)
180. Batsaikhan B, Huang CI, Yeh ML, Huang CF, Hou NJ, Lin ZY, Chen SC, Huang JF, **Yu ML**, Chuang WL, Lee JC, Dai CY\*. **2018**. The effect of antiviral therapy on serum lipid profiles in chronic hepatitis C. *Oncotarget.* 2018 Apr 20;9(30):21313-21321. (2016, IF: 5.168, Oncology: 44/217=20.27%)

#### 2017 First Author or Corresponding Author

181. Tsai PC, Huang CF, **Yu ML\***. **2017**. Unexpected early tumor recurrence in patients with hepatitis C virus-related hepatocellular carcinoma undergoing interferon-free therapy: Issue of the interval between HCC treatment and antiviral therapy. *J Hepatol* Feb;66(2):464. (2020, IF: 25.083, Gastroenterology & Hepatology: 2/92=2.17%)
182. **Yu ML\***. **2017**. Short duration of direct-acting antivirals for acute HCV infection. *Lancet Infect Dis.* May; 17(5):481-482. (2020, IF: 25.071, Infectious Diseases: 1/93=1.08%)
183. **Yu ML**. **2017**. Resistance-Associated Substitutions in Short Duration of Interferon-Free Direct-Acting Antivirals for Hepatitis C. *Gastroenterology.* 2017, Sep;153(3):867 (2020, IF: 22.682, Gastroenterology & Hepatology: 4/92=4.35%)
184. **Yu ML**. **2017**. Association Between Screen-detected Gallstone Disease and Cancer in a Cohort Study. *Gastroenterology.* 2017 Nov;153(5):1453. (2020, IF: 22.682, Gastroenterology & Hepatology: 4/92=4.35%)
185. **Yu ML\***, Huang CF, Yeh ML, Tsai PC, Huang CI, Hsieh MH, Hsieh MY, Lin ZY, Chen SC, Huang JF, Dai CY and Chuang WL. **2017**. Time-degenerative factors and the risk of hepatocellular carcinoma after antiviral therapy among hepatic C virus patients: a model for prioritization of treatment. *Clin Cancer Res.* Apr 1;23(7):1690-1697. (2020, IF: 12.531, Oncology: 18/242=7.44%)
186. Huang CF, Huang CY, Yeh ML, Wang SC, Chen KY, Ko YM, Lin CC, Tsai YS, Tsai PC, Lin ZY, Chen SC, Dai CY, Huang JF, Chuang WL, **Yu ML\***. **2017**. Genetics Variants and Serum Levels of MHC Class I Chain-related A in Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis C Patients Post Antiviral Treatment. *EBioMedicine* 15:81-89. (2020, IF: 8.143, Medicine, Research & Experimental : 17/140=12.14%)
187. Chojiilsuren G, Zhou RS, Chou SF, Chang CJ, Yang HI, Chen YY, Chuang WL, **Yu ML\***, Shih C\*. **2017**. Heparin at physiological concentration can enhance PEG-free in vitro

- infection with human hepatitis B virus. *Sci Rep*. 2017 Oct 31;7(1):14461. (2020, IF: 4.38, Multidisciplinary sciences: 17/72=23.61%)
188. Yu ML\*. 2017. Hepatitis C Treatment From "Response-guided" to "Resource-guided" therapy in the transition era from IFN-containing to IFN-free regimens. *J Gastroenterol Hepatol*. 2017 Aug;32(8):1436-1442. (2020, IF: 4.029, Gastroenterology & Hepatology: 45/92=48.91%)
  189. Yeh ML, Huang CF, Hsieh MH, Ko YM, Chen KY, Liu TW, Lin YH, Liang PC, Hsieh MY, Lin ZY, Chen SC, Huang CI, Huang JF, Kuo PL, Dai CY\*, Yu ML\*, Chuang WL. 2017. Reactivation of hepatitis B in patients of chronic hepatitis C with hepatitis B virus infection treated with direct acting antivirals. *J Gastroenterol Hepatol*. Oct;32(10):1754-1762. (2020, IF: 4.029, Gastroenterology & Hepatology: 45/92=48.91%)
  190. Huang CF, Huang CI, Yeh ML, Hou C, Hou NJ, Hsieh MY, Huang JF, Chen SC, Lin ZY, Dai CY, Chuang WL and Yu ML\*. Disease severity and erythropoiesis in chronic hepatitis C. *J Gastroenterol Hepatol*. 2017. Apr;32(4):864-869. (2020, IF: 4.029, Gastroenterology & Hepatology: 45/92=48.91%)
  191. Huang CF, Yu ML\*. 2017. Treating hepatitis C in the elderly: pharmacotherapeutic considerations and developments. *Expert Opin Pharmacother*. 2017 Dec;18(17):1867-1874. (2020, IF: 3.889, Pharmacology & Pharmacy: 117/276=42.39%)
  192. Wang SC, Lai KR, Li CY, Chiang CS, Yu GY, Sakamoto N, Tu WY, Hsieh MH, Huang JF, Chuang WL, Dai CY\*, Yu ML\*. 2017. The Paradoxical Effects of Different Hepatitis C Viral Loads on Host DNA Damage and Repair Abilities. *PLoS One*. Jan 4;12(1):e0164281. (2020, IF: 3.24, Multidisciplinary sciences: 26/72=36.11%)
  193. Tsai PC, Liu TW, Hsieh MH, Yeh ML, Liang PC, Lin YH, Huang CI, Huang CF, Hsieh MY, Hou NJ, Lin ZY, Chen SC, Huang JF, Dai CY, Chuang WL, Yu ML\*. 2017. A real-world impact of cost-effectiveness of pegylated interferon/ribavirin regimens on treatment-naïve chronic hepatitis C patients in Taiwan. *Kaohsiung J Med Sci*. Jan;33(1):44-49. (2020, IF: 2.744, Medicine, Research & Experimental: 93/140=66.43%)
  194. Tsai PC, Liu TW, Yu ML\*. Reply to "cost effectiveness of hepatitis C treatments: Need for a comprehensive evaluation". *Kaohsiung J Med Sci*. 2017 Nov;33(11):586. Epub 2017 Jul 13. PMID: 29050678. (2020, IF: 2.744, Medicine, Research & Experimental: 93/140=66.43%)
  195. Tsai PC, Liu TW, Tsai YS, Ko YM, Chen KY, Lin CC, Huang CI, Liang PC, Lin YH, Hsieh MY, Hou NJ, Huang CF, Yeh ML, Lin ZY, Chen SC, Dai CY, Chuang WL, Huang JF, Yu ML\*. 2017. Identification of groups with poor cost-effectiveness of peginterferon plus ribavirin for naïve hepatitis C patients with a real-world cohort and database. *Medicine (Baltimore)*. 2017 Jun;96(22):e6984. (2020, IF: 1.889, Medicine, General & Internal: 99/167=59.28%)
  196. Huang CF, Yeh ML, Huang CI, Lin YJ, Tsai PC, Lin ZY, Chan SY, Chen SC, Yang HI, Huang JF, Lu SN, Dai CY, Jen CL, Yuan Y, L'Italien G, Wang LY, Lee MH\*, Yu ML\*, Chuang WL, Chen CJ. 2017. Risk of hepatitis C virus related hepatocellular carcinoma between subjects with spontaneous and treatment-induced viral clearance. *Oncotarget*. Jul 4;8(27):43925-43933. (2016, IF: 5.168, Oncology: 44/217=20.27%)
  197. Huang CF, Huang CI, Yeh ML, Wang SC, Chen KY, Ko YM, Lin CC, Tsai YS, Tsai PC, Lin ZY, Chen SC, Dai CY, Huang JF, Chuang WL, Yu ML\*. 2017. Diversity of the association of serum levels and genetic variants of MHC class I polypeptide-related chain A with liver fibrosis in chronic hepatitis C. *Oncotarget*. 2017 May 16;8(20):32618-32625. (2016, IF: 5.168, Oncology: 44/217=20.27%)
  198. Tsai WL, Chang TH\*, Sun WC, Chan HH, Wu CC, Hsu PI, Cheng JS\*, Yu ML\*. Metformin activates type I interferon signaling against HCV via activation of adenosine monophosphate-activated protein kinase. *Oncotarget*. 2017 Aug 14;8(54):91928-37. (2016, IF: 5.168, Oncology: 44/217=20.27%)
  199. Lin CW, Lin CC, Lee PH, Lo GH, Hsieh PM, Koh KW, Lee CY, Chen YL, Dai CY, Huang JF, Chuang WL, Chen YS\*, Yu ML\*. The autophagy marker LC3 strongly predicts immediate mortality after surgical resection for hepatocellular carcinoma. *Oncotarget*. 2017 Aug 1;8(54):91902-91913. (2016, IF: 5.168, Oncology: 44/217=20.27%)

#### 2017 Co-author

200. Younossi ZM\*, Tanaka A, Eguchi Y, Lim YS, Yu ML, Kawada N, Dan YY, Brooks-Rooney C, Negro F and Mondelli MU. The impact of hepatitis C virus outside the liver: evidence from Asia. *Liver Int*. 2017. Feb;37(2):159-172. (2020, IF: 5.828, Gastroenterology & Hepatology: 25/92=27.17)

201. Tai CM, **Yu ML**, Tu HP, Huang CK, Hwang JC, Chuang WL\*. **2017**. Derivation and validation of a scoring system for predicting nonalcoholic steatohepatitis in Taiwanese patients with severe obesity. *Surg Obes Relat Dis*, 2017 Apr;13(4):686-692. (2020, IF: 4.734, Surgery: 30/211=14.22%)
202. Lee MH\*, Huang CF, Lai HC, Lin CY, Dai CY, Liu CJ, Wang JH, Huang JF, Su WP, Yang HC, Kee KM, Yeh ML, Chuang PH, Hsu SJ, Huang CI, Kao JT, Chen CC, Chen SH, Jeng WJ, Yang HI, Yuan Y, Lu SN, Sheen IS, Liu CH, Peng CY, Kao JH, **Yu ML**, Chuang WL, Chen CJ. **2017**. Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients. *Sci Rep*. **2017** Jun 16;7(1):3718. (2020, IF: 4.38, Multidisciplinary sciences: 17/72=23.61%)
203. Huang JF, Ko YM, Huang CF, Yeh ML, Dai CY, Hsieh MH, Huang CI, Yang HL, Wang SC, Lin ZY, Chen SC, **Yu ML**, Chuang WL. **2017**. 25-hydroxy Vitamin D Suppresses Hepatitis C Virus Replication and Contributes to Rapid Virological Response of Treatment Efficacy. *Hepatol Res*. Dec;47(13):1383-1389. (2020, IF: 4.288, Gastroenterology & Hepatology: 39/92=42.39%)
204. Holmes JA, **Yu ML**, Chung RT. **2017**. Hepatitis B reactivation during or after direct acting antiviral therapy - implication for susceptible individuals. *Expert Opin Drug Saf*. 2017 Jun;16(6):651-672 (2020, IF: 4.25, Pharmacology & Pharmacy: 94/276=34.06%)
205. Kao JH, **Yu ML**, Peng CY, Heo J, Chu CJ, Chang TT, Lee YJ, Hu TH, Yoon KT, Paik SW, Lim YS, Ahn SH, Isakov V, McPhee F, Hu W, Swenson ES, Yin PD, Treitel M\*. **2017**. Daclatasvir/asunaprevir/beclabuvir, all-oral, fixed-dose combination for patients with chronic hepatitis C virus genotype 1. *J Gastroenterol Hepatol*. 2017 Dec;32(12):1998-2005. (2020, IF: 4.029, Gastroenterology & Hepatology: 45/92=48.91%)
206. Huang JF, Yeh ML, Huang CF, Huang CI, Tsai PC, Tai CM, Yang HL, Dai CY, Hsieh MH, Chen SC, **Yu ML**, Chuang WL\*. **2017**. Cytokeratin-18 and uric acid predicts disease severity in Taiwanese nonalcoholic steatohepatitis patients. *PLoS One*. 2017 May 4;12(5):e0174394. (2020, IF: 3.24, Multidisciplinary sciences: 26/72=36.11%)
207. Jang TY, Lin PC, Huang CI, Liao YM, Yeh ML, Zeng YS, Liang PC, Hsu WY, Tsai SP, Lin ZY, Chen SC, Huang JF, Dai CY, Huang CF\*, Chiou SS\*, Chuang WL, **Yu ML**. **2017**. Seroprevalence and clinical characteristics of viral hepatitis in transfusion-dependent thalassemia and hemophilia patients. *PLoS One*. 2017 Jun 9;12(6):e0178883. (2020, IF: 3.24, Multidisciplinary sciences: 26/72=36.11%)
208. Vutien P, Jin M, Le MH, Nguven P, Trinh S, Huang JF, **Yu ML**, Chuang WL, Nguven MH\*. **2017**. Regional differences in treatment rates for patients with chronic hepatitis C infection: Systematic review and meta-analysis. *PLoS One*. 2017 Sep 6;12(9):e0183851. (2020, IF: 3.24, Multidisciplinary sciences: 26/72=36.11%)
209. Yeh ML, Huang CI, Huang CF, Hsieh MY, Lin ZY, Huang JF, Dai CY, **Yu ML**, Chen SC\*, Chuang WL. **2017**. The impact of an additional extra-hepatic primary malignancy on the outcomes of patients with hepatocellular carcinoma. *PLoS One*. 2017 Sep 28;12(9):e0184878. (2020, IF: 3.24, Multidisciplinary sciences: 26/72=36.11%)
210. Lin TY, Yeh ML, Huang CI, Chen YL, Dai CY, Huang JF, Lin ZY, Chen SC, Huang CF\*, **Yu ML**, Chuang WL. **2017**. Pegylated interferon plus ribavirin combination therapy in postliver transplant recipients with recurrent hepatitis C virus infection. *Kaohsiung J Med Sci*. 2017 Jun;33(6):284-289. (2020, IF: 2.744, Medicine, Research & Experimental: 93/140=66.43%)
211. Huang CI, Huang CF, Yeh ML, Lin YH, Liang PC, Hsieh MH, Dai CY, Hsieh MY, Lin ZY, Chen SC, Huang JF\*, **Yu ML**, Chuang WL. **2017**. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein expression predicts disease severity in chronic hepatitis C patients. *Kaohsiung J Med Sci*. 2017 Aug;33(8):394-399. (2020, IF: 2.744, Medicine, Research & Experimental: 93/140=66.43%)
212. Tsai JF\*, Chen SC, Lin ZY, Dai CY, Huang JF, **Yu ML**, Chuang WL. **2017**. Interactive effects between Lymphotoxin alpha +252 polymorphism and habits of substance use on risk of hepatocellular carcinoma. *Kaohsiung J Med Sci*. 2017 Jul;33(7):334-338. (2020, IF: 2.744, Medicine, Research & Experimental: 93/140=66.43%)
213. Tsai JF\*, Chen SC, Lin ZY, Dai CY, Huang JF, **Yu ML**, Chuang WL. **2017**. Independent and additive interaction between polymorphisms of tumor necrosis factor alpha-308 and lymphotoxin alpha+252 on risk of hepatocellular carcinoma related to hepatitis B. *Kaohsiung J Med Sci*. 2017 Sep;33(9):453-457. (2020, IF: 2.744, Medicine, Research & Experimental: 93/140=66.43%)
214. Huang JF, Huang CF, Yeh ML, Dai CY, Hsieh MH, Yang JF, Huang CI, Lin YH, Liang PC, Lin ZY, Chen SC, **Yu ML**, Chuang WL\*. **2017**. The outcomes of glucose abnormalities in

- chronic hepatitis C patients receiving interferon-free direct antiviral agents. *Kaohsiung J Med Sci.* 2017 Nov;33(11):567-571. (2020, IF: 2.744, *Medicine, Research & Experimental*: 93/140=66.43%)
215. Hsieh MH, Yang JF, Lin WY, Chien HH, Kuo MC, Chang NC, Wang CL, Chuang WL, Yu ML, Dai CY\*. 2017. Fasting sugar, blood pressure, and uric acid are factors related to positive proteinuria and an impaired eGFR. *J Chin Med Assoc.* 2017 Dec;80(12):782-789. (2020, IF: 2.743, *Medicine, General & Internal*: 62/167=37.13%)